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1 aBstraCt
Screening for cervical cancer has the potential to reduce cancer incidence and can-
cer death by over 80%, but this level of effect requires an organised programme 
with integrated quality assurance. Screening is a complex process that relies on 
the optimal configuration and functioning of a number of components, including 
determination of the target population, formulation of the screening protocol, in-
vitation coverage, efforts to maintain high attendance rates, validity of the screen-
ing test, and the follow-up and management of screen positives. Monitoring of 
performance indicators and, especially, process audits are needed for identification 
and rectification of any barriers to effectiveness in the screening chain. In addition, 
periodic evaluation of the effects of the screening activity on incidence and mortal-
ity endpoints is needed, as the risk factors for the population may change between 
areas and with time.
The aim of this study was to evaluate the performance and age-specific effec-
tiveness of cervical cancer screening, by focusing on audit studies of the Finnish 
cervical cancer screening programme within case–control designs with information 
on the outcome of screening. The study also developed further quality assurance 
protocols for integration into the programme. Good quality of process and outcome 
registration is required for reliable quality assurance activities. The coverage and 
accuracy of data on screen-detected lesions and cancers in the screening register 
were evaluated via individual linkage to two other health care registers. Precancer-
ous and cancerous lesions arising in the screened population were used in an audit 
of cytology wherein screening-test validity in programme service laboratories was 
evaluated with a focus on sensitivity failures in the form of false negative screening 
results. Cytodiagnosis sensitivity, specificity, and reproducibility were evaluated in 
a review phase involving both case and control smears. Outcome measures were 
also related to cross-sectional performance indicators, and variations between labo-
ratories were explored.
The mode of detection and screening history was determined for every cancer 
case diagnosed in Finland in 2000–2009. A separate audit of screening histories 
was performed for deaths from cervical cancer in the same period. Population-based 
controls were used in estimation of the agespecific effectiveness of the organised 
programme in a case–control design. We were also able to perform age-specific 
self-selection bias corrections of the effectiveness estimates, which should ensure 
more informative results.
The quality of the screening and cancer registers is such that reliable monitor-
ing and also individual case audits are possible. We found that some analytical 
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failures as measured in terms of false-negative rates of case smears do occur in 
the programme but that their impact on cancer incidence is small. However, the 
reproducibility of the cytodiagnosis and variations in the specificity of the screen-
ing laboratories should be addressed by means of cytology audits and feedback to 
the screeners.
A large proportion of the cervical cancers and most deaths from cervical cancer 
occur at ages above the currently recommended invitational ages. Only a very small 
proportion of the burden arises before first invitation. Non-attenders contribute 
significantly to incidence and mortality, and a smaller proportion of cases can be 
attributed to screening failures. Management of screening positives appears to be 
excellent. The effectiveness of screening, as measured by the reduction in the risk 
of cervical cancer and death from cervical cancer associated with participation in 
organised screening, was strongly dependent on age. Screening at ages below 40 
and, especially, below 30 was associated with a clearly smaller risk reduction than 
screening at 40 and above. Also the duration of the protective effect was age-de-
pendent. These findings refer specifically to participation in the organised screening 
programme against a backdrop of considerable opportunistic screening activity.
In light of these audit studies, one can see that most cancers and cancer deaths 
currently occur because of a lack of screening, either among non-attenders of the 
screening programme or women outside the screening ages, and not because of low 
quality of the screening test or management process. Variability of performance and, 
especially, of the laboratories’ specificity still warrants regular feedback and harmo-
nisation, so that the adverse effects caused by false positives are kept at a minimum. 
Monitoring and audits of the screening programme are clearly important for the 
programme’s development and further optimisation. Also changing circumstances 
such as reorganisation of screening and the associated health service providers, and 
dynamic risk factors in the population require constant vigilance and the ability to 
detect and respond to developing threats to the effectiveness of the programme.
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2 finnish summary
Kohdunkaulasyövän seulonnalla voidaan ehkäistä yli 80% syövistä ja syöpään liit-
tyvistä kuolemista. Tämän tasoinen vaikutus vaatii kuitenkin toteutuakseen hy-
vin organisoidun seulontaohjelman jonka yhtenä olennaisena osana on riittävän 
systemaattinen laadunvarmistus. Tehokas seulonta on monen osatekijän summa. 
Seulontaohjelman tehoon vaikuttavat kohdeväestön määrittely, seulontakäytännöt, 
kutsujen peittävyys, osallistumisaste, seulontatestin osuvuus ja seulontapositiivisten 
jatkotutkimusten ja hoitojen laatu. Prosessia kuvaavien määreiden seuraaminen ja 
etenkin päätetapahtumiin perustuva auditointi mahdollistavat vaikuttavuutta ra-
joittavien tekijöiden yksilöimisen ja korjaamisen. Myös vaikuttavuusasteen arviointi 
ilmaantuvuus- ja kuolleisuusmittareilla esimerkiksi eri ikäryhmissä on tarpeen sillä 
populaatioryhmien riskitekijät voivat muuttua ajan myötä.
Tämän väitöskirjatyön tavoitteena oli tutkia kohdunkaulan syöpää ehkäise-
vän seulonnan diagnostinen laatu ja ikäspesifi vaikuttavuus. Tutkimus paneutui 
Suomen seulontaohjelmassa tapaus-verrokki –asetelmissa tehtyihin audititoin-
titutkimuksiin, joissa seulonnan päätetapahtumista saatavilla oleva informaatio 
otettiin huomioon.  Tutkimus myös kehitti seulontaohjelmaan pysyvästi liitettäviä 
laadunvarmistustoimintoja päätetapahtumien auditointiin perustuen. Rekisteritie-
don laatu on olennainen edellytys luotettavalle laadunvarmistustoiminnalle. Seu-
lontarekisterin seulontalöydöstiedon kattavuutta ja oikeellisuutta arvioitiin yhdis-
tämällä tietoja kolmesta eri terveydenhuoltoon liittyvästä rekisteristä. Sytologisen 
seulontatestin auditointiin käytettiin esiaste- ja syöpätietoja. Testin osuvuutta ar-
vioitiin erityisesti väärien negatiivisten osalta. Uudelleenluentavaiheessa arvioitiin 
myös seulontatestin herkkyyttä, tarkkuutta ja toistettavuutta. Seulonnan jälkeisten 
päätetapahtumien suhdetta seulontaprosessia kuvaaviin parametreihin arvioitiin 
laboratoriokohtaisesti.
Suomen 2000-luvun syöpätapahtumien diagnoositapa ja seulontahistoria mää-
ritettiin yhdistämällä syöpärekisterin kattavat syöpätiedot seulontarekisterin tietoi-
hin. Väestöpohjaisten verrokkien avulla arvioitiin seulontatestin ikäryhmäkohtaista 
vaikuttavuutta ilmaantuvuuteen ja kuolleisuuteen. Ehkä ensimmäistä kertaa pys-
tyimme myös määrittämään ikäryhmäkohtaisen osallistumisharhan jonka avulla 
korjattujen vaikuttavuusestimaattien absoluuttinen informaatioarvo todennäköi-
sesti parani huomattavasti.
Seulonta- ja syöpärekisteritiedon laatu on korkeaa tasoa ja mahdollistaa näin 
ollen luotettavan laadunvarmistustoiminnan ja tapausten auditoimisen. Seulonta-
ohjelmassa tapahtuu jonkin verran analyysivirheitä mutta näiden vaikutus syövän 
ilmaantuvuuteen on pieni. Sytologisen diagnoosin toistettavuus ja laboratoriokoh-
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taisen testitarkkuuden vaihtelut kuitenkin vaativat prosessin tarkkailua, palautteen 
antamista ja toiminnan kehittämistä myös jatkossa.
Suuri osa kohdunkaulan syövistä ja suurin osa kuolemista ajoittuvat diagnoosil-
taan seulontaohjelman viimeisen kutsun jälkeiseen aikaan naisen elämässä. Tämä 
kuvastaa osaltaan seulontaikäryhmiin kohdistuvan seulonnan vaikuttavuutta koska 
seulomattoman väestön kohdunkaulan syövästä aiheutuva taakka ajoittuu paljon 
nuorempaan väestöön. Toisaalta vain hyvin pieni osa syövistä diagnosoidaan ennen 
ensimmäistä seulontakutsua. Seulontaan osallistumattomat naiset muodostavat 
toiseksi suurimman joukon ja pienempi osa kohdunkaulan syövistä ja kuolemis-
ta kohdistuu seulontaan osallistuneiden joukkoon. Positiivisten seulontalöydös-
ten hoidon ja seurannan laatu vaikuttaa erinomaiselta. Seulontaan osallistumisen 
ja päätetapahtumien riskin välinen yhteys oli ikäriippuvainen, siten että alle 40 
vuoden, ja etenkin alle 30 vuoden iässä tapahtuvalla ohjelmaseulonnalla arvioitiin 
olevan selvästi pienempi vaikutus kuin 40:n ja sitä vanhempien seulonnalla. Myös 
seulonnan riskiä pienentävän vaikutuksen kesto kasvoi iän kasvaessa. Tutkimuksen 
tulokset kuvaavat nimenomaan organisoituun seulontaohjelmaan osallistumisen 
vaikutuksia. Ohjelman lisäksi ja organisatorisesti siitä riippumatta väestö on myös 
merkittävän opportunistisen seulontatoiminnan kohteena.
Tutkimustulosten valossa voidaan todeta että suurin osa kohdunkaulan syö-
vistä ja niihin liittyvistä kuolemista johtuvat seulonnan puutteesta, jolloin nainen 
ei ollut osallistunut organisoituun seulontaan kutsun saatuaan tai oli iältään seu-
lontaikäryhmien ulkopuolella, eikä niinkään seulonnan laadun puutteista. Labora-
toriotoiminnan ja etenkin seulontatestin tarkkuuden vaihtelut kuitenkin vaativat 
palautejärjestelmää jotta toiminta voitaisiin yhdenmukaistaa ja vääristä positii-
visista testivastauksista johtuvat haittavaikutukset minimoida. Seulontaohjelman 
vaikuttavuuden ylläpitäminen ja edelleen kehittäminen vaatii laadunvarmistustoi-
mintaa ja syöpätapausten auditointitutkimuksia myös jatkossa. Myös olosuhteiden 
muutokset, kuten terveyspalveluketjujen organisaatiomuutokset ja riskitekijöiden 
muutokset väestössä, vaativat jatkuvaa valmiutta havaita ja puuttua seulonnan vai-
kuttavuutta uhkaaviin tekijöihin.
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AGC-NOS atypical glandular cells – not otherwise specified
AIS adenocarcinoma in situ
ASC-H atypical squamous cells – high-grade cannot be ruled out
ASC-US atypical squamous cells – undetermined significance
CIN1-3 cervical intraepithelial neoplasia, grade 1–3 
CIN1-3+ CIN1-3 or worse
CIN3/AIS CIN3 or adenocarcinoma in situ
ENCR European Network of Cancer Registries
FCR Finnish Cancer Registry (or Register)
HDR Care Registers for Social Welfare and Health Care (formerly known 
as the Hospital Discharge Register)
HPV human papillomavirus
hrHPV high-risk HPV
HSIL high-grade squamous intraepithelial lesion
ICC invasive cervical cancer
ICD-10 International Classification of Diseases – 10th edition
ICD-O-3 International Classification of Diseases for Oncology – 3rd edition
LSIL low-grade squamous intraepithelial lesion
MSR Mass Screening Registry (or Register)
NHS National Health Service (British health service provider)
NOS not otherwise specified
NPV negative predictive value
Pap I–V  Papanicolaou class I–V
Pap smear cytological smear stained with the Papanicolaou method
PPV positive predictive value
SCC squamous cell carcinoma (of the cervix)
THL Terveyden ja Hyvinvoinnin Laitos (Finland’s National Institute of 
Health and Welfare)
WHO World Health Organization
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5 introduCtion
Cervical cancer screening via sampling of cells directly from the cervix, endocervix, 
and vagina has over the past half-century proved to be a very effective way of pre-
venting the development of invasive cervical disease. The detection of abnormal 
cells in cervical scrapings or pap smears and subsequent diagnostic confirmation 
by colposcopy allow the excision of lesions at risk of becoming malignant. Cervi-
cal cancer has several properties that make it particularly suitable for screening. 
It usually develops via premalignant lesions in squamous or glandular epithelial 
cells visible in the transformation zone and the junction between these two dif-
ferent epithelia. The transformation zone and junction is visible at younger ages 
at the ectocervix surface. At older ages, because of the metaplastic process, the 
junction often withdraws into the endocervical canal and may not be visible, even 
if still accessible for sampling. Hence, direct sampling of the potentially abnormal 
exfoliated cells can usually be performed without invasive procedures. Crucially, 
cervical cancer develops from a long-lasting and treatable premalignant phase that 
is suitable for detection by cytology and related histology.
Despite these advantages, the effectiveness of screening programmes has been 
widely variable. In some settings, large reductions in both incidence and mortal-
ity of cervical cancer have been achieved, but in many cases impacts have been 
disappointingly low or even absent (IARC 2005, Anttila et al. 2009, Arbyn et al. 
2009b). In order for the beneficial effects of screening to materialise, the entire 
chain from screening coverage to quality of treatment and follow-up has to be 
carefully controlled and optimised (EC 2003, IARC 2005, Arbyn et al. 2008a). 
Comprehensive quality assurance for the screening process is possible only in the 
context of the organised and population-based screening programme. The quality 
of an individually tailored or opportunistic screening service can be excellent but 
is usually not consistently so and in any case remains very difficult to monitor, 
evaluate, and hence improve.
Comprehensive quality assurance for a screening programme can be viewed as 
comprising both monitoring and evaluation. Monitoring includes the tracking of 
cross-sectional performance indicators – for instance, as specified in the European 
guidelines – but also outcome-based longitudinal indicators such as interval cancer 
rates are needed (Arbyn et al. 2008a). The derivation of outcome indicators requires 
the linkage of screening and cancer registers and the construction of screening his-
tory for all cancers – in other words, an audit of cervical cancer cases. A complete 
audit also entails review of both cytological screening tests and any histological slides, 
preferably with controls for reduced subjective evaluation bias. However, there are 
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crucial questions related to the optimisation of a screening programme that cannot 
be addressed with information derived from monitoring alone (for example the 
appropriate screening ages and intervals in a particular population); hence, in ad-
dition to continuous monitoring of a programme, it is necessary that there also be 
periodic evaluation studies performed with a cohort–control or case–control design. 
The ideal, then, is an organised population-based screening programme with 
quality assurance at every step in the screening chain; regular audits of all incident 
cancer cases; and evaluation of efficacy, effectiveness, benefit/harm ratio, and cost 
(Sasieni and Cuzick 2001, Arbyn et al. 2008a). Such a programme will continuously 
produce information about possible barriers to optimal impact and allow dynamic 
responses to changes in the quality of component functions or in the risk profile of 
the targeted population (Andrae and Smith 1999).
The objective of this work was to develop and pilot components of quality as-
surance for integration into the cervical cancer screening programme and in the 
process to gain knowledge of the barriers to effectiveness and areas showing po-
tential for improvement.
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6 review of the literature
6.1 CerviCal CanCer and intraepithelial neoplasia
The uterine cervix is the part of the uterus that projects into the upper part of the 
vagina. Two types of epithelia converge at the cervix. Stratified squamous epithelial 
cells line the inside of the vagina and most of the ectocervical surface, and glandular 
epithelial cells line the endocervical canal and also mucus-secreting glandular crypts 
within the squamous epithelium. At the onset of puberty, a considerable area of 
the ectocervix is covered by columnar epithelium, but gradually the squamoco-
lumnar junction starts to migrate from the periphery of the ectocervix toward the 
endocervical canal through squamous metaplasia. This is a slow replacement of the 
columnar epithelium by squamous cells. The area where squamous metaplasia takes 
place is called the transformation zone. The cells of the transformation zone are 
especially susceptible to HPV-induced neoplastic transformation, and this is where 
most squamous-cell carcinomas of the cervix develop (IARC 2005, IARC 2007). 
Similarly, columnar cells near the transformation zone and in the endocervical 
canal are believed to give rise to adenocarcinomas of the cervix.
Persistent infection by certain high-risk types of HPV is necessary for the de-
velopment of both squamous and adenomatous cervical cancers (zur Hausen 1976, 
Bosch et al. 1995, Munoz et al. 2003). Of over 130 known types of HPV, about 40 
can infect the genital mucosa, and 18 of the latter are termed high-risk types because 
of their ability to immortalise squamous epithelial cells (de Villiers et al. 2004).
Most sexually active women will contract a genital HPV infection at some point 
in life, and the prevalence is especially high at young ages, a few years after sexual 
debut (Rodriguez et al. 2007). In a cohort of university students in Finland, the 
prevalence of HPV in the lower genital tract was 33% (Auvinen et al. 2005). However, 
the majority of HPV infections are cleared by host defences within 6–12 months 
without complications, even when the causative agent is of an hrHPV type (Berkhof 
et al. 2005). When infection persists, there is a risk of neoplastic transformation 
and the development of precancerous lesions and cervical cancer.
Neoplastic cervical lesions of squamous-cell origin can be classified by the 
thickness of atypical, abnormal cells within the epithelium and by their cellular 
characteristics into cervical intraepithelial neoplasia (CIN) of grades 1–3. Lesions 
classified as CIN1 can be caused by both low- and high-risk types of HPV, and the 
risk of progression to cervical cancer is low. CIN2 and CIN3 are predominantly 
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associated with high-risk types, and the risk of progression is higher. An early 
Finnish study estimated that 28–39% of severe dysplasia and carcinoma in situ 
cases combined (equivalent to CIN3) will progress to invasive cancer (Hakama 
and Räsänen-Virtanen 1976). Progressive proportions observed in a study of un-
treated CIN3 cases in New Zealand with 30 years of follow-up (McCredie et al. 
2008) and in a study using data from Canada’s British Columbia screening pro-
gramme (van Oortmarssen and Habbema 1991) fall within the same range (at 
31% and 38%, respectively), though these proportions may be underestimates of 
true undisturbed progressive potential and show strong variation with age. The 
latter study also provided evidence of higher regression rates at younger ages.
The development of cervical cancer from hrHPV infection through stages of 
precancerous lesions is usually a slow process. A case–control study nested in a 
cohort of women screened in the Swedish screening programme estimated the 
mean incubation period from first confirmed HPV 16 infection to detection of 
carcinoma in situ at the cervix uteri to be 17–19 years, depending on the viral 
load (Ylitalo et al. 2000). In a modelling study based on data from the British 
Columbia screening programme, the average duration of the dysplasia and car-
cinoma in situ stages combined was estimated at 11.8 years (van Oortmarssen 
and Habbema 1991).
Squamous-cell carcinomas make up the bulk of cervical cancers, in the range of 
80–90% in an unscreened population. The second most common group, the ad-
enocarcinomas, originate in the columnar epithelial cells of the cervix. The natural 
history of this group is not very well charted, but an adenocarcinoma in situ (AIS) 
stage is commonly recognised. Some other histopathological types of carcinomas 
and a small number of stromal malignancies (mainly sarcomas) are also counted 
among cervical cancers. 
6.2 sCreening for CerviCal CanCer
Screening is the use of methods of detecting unrecognised health risks or dis-
eases in order to permit timely intervention (IARC 2005). The development of 
the first specifications for the requirements of screening was commissioned by 
the WHO and published in 1968 (Wilson and Jungner 1968). These principles 
are designed to ensure continuous and universal access to a screening service 
with the necessary biological and organisational conditions in place for a positive 
health impact at acceptable cost. More recently, the psychological and physical 
harm of screening, especially that related to false-positive tests, over-diagnosis, 
and over-treatment, has been brought into focus (Arbyn et al. 2008c, Hellsten 
et al. 2008).
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The primary aim of cervical screening is to reduce incidence and mortality of 
cervical cancer. A secondary aim can be to improve cure rates via screen-detection 
of non-symptomatic cancers. There are three major types of screening tests suit-
able for achieving these aims. The predominant screening modality is based on 
the microscopy of exfoliated cells from the cervical epithelium. This technique was 
proposed by the Greek pathologist Papanicolaou (Papanicolaou and Traut 1941) 
and has been used to great effect in cervical screening. Modifications of this tech-
nique include automation-assisted analysis and liquid-based cytology (Nieminen 
et al. 2003, Arbyn et al. 2008b). Cytology-based screening tests are an attempt to 
identify abnormal cells that indicate the presence of a precancerous lesion. After 
diagnostic confirmation by colposcopy and biopsies, lesions can be excised, whereby 
the development of invasive disease is prevented. The second modality is based on 
detection of the presence of high-risk HPV. As persistent HPV infections precede 
the development of neoplastic cellular changes, the disease process may be detect-
able with an HPV test at even earlier stages than with cytology. The HPV tests in 
most common use are based on the detection of viral DNA from cellular material. 
Also RNA and viral protein assays have been developed, but these have not yet 
been clinically validated for cancer screening purposes. The third modality is visual 
inspection of the cervix, usually aided by acetic-acid treatment of the epithelium. 
This method is used in low-resource settings (Sankaranarayanan et al. 2007).
6.3 the audit of CerviCal CanCer Cases
6.3.1 definition
Cervical cancer screening is a complex procedure the outcome of which depends 
on seamless collaboration of several functions. The performance of the process can 
indirectly be observed in trends of cervical cancer incidence and mortality, but if 
one is to develop and optimise the programme, detailed information about the 
performance of component functions is needed. As with any large-scale process, 
an effective way of gaining useful insights into the performance is to examine the 
failures of the process (Cuzick 2008). The failures of cervical screening are women 
who develop (potentially fatal) cervical cancer.
Screening histories of cervical cancer cases have long been of interest to screen-
ing organisers and screening professionals, and there are examples of published 
case series from the 1970s and 1980s (Rylander 1976, Grundsell et al. 1979, Dunn 
and Schweitzer 1981, Brown and Barker 1982, Yajima et al. 1982). Proposals for 
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more systematic audits including smear reviews were probably first made in the 
UK in the 1980s (Chamberlain 1984), resulting in pilot audit studies in the 1990s 
(Slater et al. 1994, Sasieni et al. 1996) and in formalised audit specifications being 
published in 2006 by the NHS (NHS Cervical Screening Programme 2006), as 
well as in the European guidelines for quality assurance in cervical cancer screen-
ing, in 2008 (Arbyn et al. 2008a). A Swedish study in 2008 was hailed as the first 
comprehensive national audit since publication of the European quality assurance 
guidelines (Andrae et al. 2008). According to specifications in these publications, 
a comprehensive audit starts with a screening history review of all invasive cervical 
cancer cases arising in the population covered by the screening programme within 
a specific span of time. Any (negative) smears preceding the diagnosis should be 
reviewed for failures of analysis (cytology audit). Any histological slides preceding 
the diagnosis could likewise be reviewed (histology audit). Controls can be used to 
alleviate the tendency to overcall audit smears that are known to precede a cancer 
diagnosis (Renshaw et al. 2004, Coleman and Poznansky 2006) but also for uncov-
ering information on the specificity of the screening test and histological evaluation 
(Arbyn et al. 2008a). The controls can be population-based controls, with sampling 
from women at risk of cervical cancer (for example, matched for age and place of 
residence), in which case the same controls can be used for a case–control analysis 
of the association of screening history with the risk of cervical cancer (Arbyn et al. 
2009a). Alternatively, direct archive specimen–control sampling can be used for 
the cytology and histology reviews (Repse-Fokter et al. 2012). 
6.3.2 audit of sCreening history
For reliable monitoring and audit of a cervical screening programme, it is essential 
to have complete registration of all cervical cancer cases and all preventive screen-
ing tests in the population. In addition, a reliable means of linking registers (e.g., 
a personal identifier) is needed. Screening history can be categorised with various 
levels of detail, depending upon available information and anticipated barriers to 
effectiveness in each particular setting. However, screen-detected cancers should be 
categorised according to the previous screening history, as the screening event lead-
ing to detection does not afford any protection. Mode of detection (by screen or by 
symptoms) is an important parameter independently associated with both stage and 
survival (Herbert et al. 2009b, Andrae et al. 2012), and it has been recommended for 
inclusion in routine cancer registration (ENCR 2001). It is not useful in the analysis 
of preventive screening history or screening failure audit, however. Table 1 illustrates 
a hierarchically organised synthesis of the types of failures that are of interest with 
respect to screening-history audits (Hakama et al. 1985, Miller 1995, Zapka et al. 
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2003, Bagnall et al. 2006). The example details a screening history categorisation 
scheme that classifies each cancer case with respect to a defined period of time 
before diagnosis (for instance, one recommended screening interval). Every cancer 
case can be placed into one of the three classes in the first column in the table. The 
classes are mutually exclusive, and the classification proceeds in order such that 
only those cases not falling into the first class are considered for the next one. Those 
not invited include women who, because of age or incomplete invitational coverage 
of the target ages, were not extended an invitation in the specified time window 
before diagnosis. Those invited can then be classified according to whether they 
participated and a preventive screening test was performed. Participating women 
can further be classified by screening test result, confirmation result, appropriateness 
of follow-up, and treatment. If a large, or increasing, proportion of cases fall into 
a specific category of screening history, a targeted evaluation should be triggered. 
For example, if most cancers were to appear outside the targeted screening ages, 
investigation into the possibility of extending the target age range might be useful.
An approach commonly used for categorising process failure is the division of 
cancer cases by screening history into failures of coverage (by invitation or partici-
pation), failures of detection (negative screening tests), and failures of management 
(failures of follow-up and treatment) (Spence et al. 2007). False-negative histopa-
thology could be taken to be a failure of detection or failure of management; usu-
ally it is considered to involve the latter. However, a more detailed specification 
will allow for more effective feedback to the screening service providers, which is 
a necessary component of an audit aimed at improvement in the effectiveness of 
the screening programme.
Most audits include all invasive cancer cases in a given population diagnosed 
during a defined period of time. However, some authors do not consider microin-
vasive carcinomas to be failures of screening, because of their extremely favour-
able prognosis (IARC 2005), and focus instead on frankly invasive cancers (stages 
IB and above). Also, audits including only fatal cases of cervical cancer have been 
published (Wilson and Johnson 1992, Slater et al. 1994, Mitchell et al. 1996) but not 
recently. Furthermore, some authors consider only SCCs to be failures of a screen-
ing programme and hence suitable as audit cases, as the effectiveness of cytological 
screening has been unequivocally established for that particular histopathological 
subspecies (IARC 1986) and smaller or non-existent protective effects have been 
observed for adenocarcinomas (Herrero et al. 1992, Makino et al. 1995, Mitchell 
et al. 1995, Mitchell et al. 2003, Zappa et al. 2004). As there is a differential as-
sociation of screening and cervical cancer by stage and histopathology, it is advis-
able to present audit and evaluation results for frankly invasive cancers and SCCs 
separately, in addition to results for all cervical cancers.
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Table 1: Screening history categorization for a cancer audit (failure analysis)
Not invited





Analytical failure (false negative)
Sampling failure
Incompatibility of test modality and natural history*
Borderline screening test





Referral compliance or organisation failure
Negative histology
Analytical failure (false negative)
Sampling failure
Positive histology
Ineffective treatment of CIN
Failure of follow-up
* Inherent test sensitivity is too low or interval is too long or both.
Table 2 lists research papers that describe the screening history of case series 
or case and control subjects where the purpose has specifically been audit research 
– i.e., to elucidate the process of care failure that allowed cervical cancers to de-
velop. These papers were selected for comparability of the proportion of cases that 
were interval cancers, defined here as cases arising after a screening test with any 
outcome but not leading to the detection of cancer, in a specified interval before 
diagnosis. Also, the papers listed consider all cervical cancers or all squamous-cell 
cervical cancers diagnosed in a specified population during a specified time and 
use screening or cytopathology registers for the construction of screening history.
The mode of detection with respect to screening can be challenging to assign 
correctly, and various approaches have been used, in different settings. In the Neth-
erlands, information on the mode of detection is available in the automated national 
pathology archive (PALGA), and diagnostic and preventive screening tests can be 
correctly distinguished (Bos et al. 2006, van der Aa et al. 2008, de Bie et al. 2011). 
In the audit in Lambeth and Southwark, London, it was also possible to distin-
guish screen-detected cancers by clinical criteria, with the definition being those 
diagnosed as a result of investigation of an abnormal cytology test (Herbert et al. 
2010). This information is now routinely collected for each woman with cancer in 
the London quality assurance database. When not directly recorded in pathology 
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or cancer registers on the basis of referral information, the identification of smears 
leading to screen-detection of cancer, as opposed to preventive smears, may be 
difficult. Some studies try to alleviate the problem by considering only frankly in-
vasive cancers (stages IB+), following the rationale that microinvasive cancers are 
usually screen-detected (Anderson et al. 1992). Other studies exclude the screening 
history immediately before diagnosis (for example, six months before), consider-
ing smears taken during that time to be part of the diagnostic process (Kenter et 
al. 1996, Andrae et al. 2008, Ingemann-Hansen et al. 2008, Herbert et al. 2009a, 
Kirschner et al. 2011). A third option is to regard all cases of cancer diagnosed within 
a certain period after referral for colposcopy based on a positive screening test to 
be screen-detected, modifying the time interval for screening history classification 
accordingly. All of these approaches yield approximations only. The first approach 
is compromised by the inevitable occurrence of frankly invasive screen-detected 
cancers, the second by the fact that screening events occurring close to diagnosis 
but not leading to detection (potentially false-negative screens) are missed when 
this period is excluded. These are important indicators of the process of care failure. 
Finally, the third approach can be unreliable if there is non-compliance with referral.
The first study in this overview is a Danish report describing the screening his-
tories of 376 women with cervical cancer diagnosed between 1979 and 1983 (Kris-
tensen et al. 1991). In the three years before diagnosis, 202 of the women, or 54% 
of all cases, had been screened. However, it is not clear whether the histories of all 
202 women included preventive screens – i.e., screening tests in addition to those 
leading to the detection of cancer. A later, and more detailed, Danish audit reported 
screening histories of 286 ICCs in Aarhus County 10 years after the implementation 
of an invitational screening programme for women aged 23–59 (Ingemann-Hansen 
et al. 2008). The screening history was based on tests five to 47 months prior to 
diagnosis, a suitable time window for preventive smears. Across all ages, 23% of 
the cases never had screening, another 38% were not screened in the last interval, 
20% involved interval cancers with a preceding negative test, 5% manifested inad-
equate follow-up after an abnormal smear, and 7% involved development of cancer 
despite adequate management of an abnormal smear. The authors conclude that 
improving participation in the programme should be given high priority.
Anderson and colleagues (1992) presented a failure analysis audit from British 
Columbia with 437 ICC cases of stages IB and above diagnosed in 1985–1988. All 
cases in the province were referred to one of two clinics, in Vancouver and Victo-
ria, and all screening tests were analysed at one central screening laboratory and 
recorded in a central cytology register. Hence, the completeness of data on both 
cancer cases and screening tests can be expected to be good. However, no descrip-
tion of the method of linkage was given in the report. There were 170 cases, 39% 
of the total, with no cytology examinations recorded and a further 10% with more 
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than five years since last cytology. The screening history was defined as screening 
tests before the presentation of invasive disease, which is somewhat vague in terms 
of the handling of screendetection. Probably the only precaution against including 
diagnostic screening tests of screen-detected cancers was the exclusion of micro-
invasive carcinomas.
Similar results were later reported from the Canadian province of Alberta, where 
the screening history and failure category of cases diagnosed in 1990–1991 were 
reported (Stuart et al. 1997). Out of 246 cases, 30% had never been screened; a 
further 15% had been screened more than three years before diagnosis; and in 
17% of the cases, the screening history could not be ascertained. Another 10 
years later, a third report from Canada reported screening histories of cases diag-
nosed in 2001–2002 in Toronto (Spayne et al. 2008). Here, 31% of the 225 ICC 
cases analysed involved a screening test within 6–48 months before diagnosis. The 
three Canadian studies show a downward trend in the proportion of cancers with 
screening tests within 3–5 years before diagnosis: 51% in British Columbia in the 
1980s, 43% in Alberta in the 1990s, and 31% in Ontario in the 2000s. It is possible 
that this trend reflects improvements in the quality of cytology and management 
services over time.
There are a number of audit studies from the UK. An early-screening failure 
analysis included 36 cervical cancer deaths in Rotherham (Slater et al. 1994). Screen-
ing history was determined for a period of eight years before diagnosis, and 53% 
of the women had been screened in this time window. One of the early pilot audit 
studies from the UK analysed screening histories of 348 invasive cancers from 24 
self-selected health districts (Sasieni et al. 1996). Tests from six months before di-
agnosis were excluded. In this material, 53% of cancers were interval cancers with 
a screening test within 66 months of diagnosis. Of all fully invasive cancers, 48% 
were interval cancers, and the corresponding proportion for all microinvasive car-
cinomas was 69%. A later study from the UK investigated the screening histories of 
cervical cancer cases in a 12-year period during introduction of organised screening 
in Southampton and south-west Hampshire (Herbert et al. 2009a). There were 
382 women with incident cervical cancer in 1986–1995. Cytology tests performed 
within six months of diagnosis were considered diagnostic and excluded from the 
screening history. Interval cancers, or cases with screening tests within 5.5 years 
of diagnosis, accounted for 45%, and 22% of these had a negative last screen. The 
study also presented an interesting figure showing proportion of interval cancers 
as a function of time since programme implementation. The proportion climbs 
initially as coverage is expanded, peaks six years later, and then starts to fall along-
side overall incidence. The proportion of cases in non-participants declines initially 
and then seems to reach a plateau. A year later, that work’s first author published 
a similar study of CIN2+ cases diagnosed in two south London boroughs (Herbert 
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et al. 2010). In addition to 3,027 precancer cases, 133 invasive cancer cases were 
diagnosed in 1999–2007. Of the cancers, for 53% there had been a screening test 
0.5–5.5 years previously. A large proportion of cancers were screen-detected in this 
audit (49%); two thirds of these were microinvasive.
In the US, screening audits have been challenging because of a lack of personal 
identifiers and comprehensive screening registers. Nevertheless, some screening 
failure analysis reports have been published. One study audited 664 cervical cancer 
cases diagnosed in Connecticut from March 1985 through February 1990 (Janerich 
et al. 1995), by collecting screening history information from physicians, patients, 
and kin. Out of the 481 with screening history available, 48% had a screening test 
within five years prior to diagnosis, and 25% within three years. The Kaiser Per-
manente Medical Care Program of northern California provides a good setting for 
monitoring and evaluation of screening in the US although data are available only 
for health plan members. Between 1988 and 1994, 455 eligible ICC cases were di-
agnosed among long-term members, and their screening histories for 6–26 months 
before diagnosis were elicited (Sung et al. 2000). Non-participation was the larg-
est category, with 53%, followed by 28% potential false negatives, 9% abnormal 
smears with correct management, and 4% with inadequate follow-up of cytological 
abnormalities. Participation was highest in the younger age groups. Interventions 
to increase participation were urged by the authors.
The screening programme in the Netherlands targeted women of ages 35–53 
from 1998 and 30–60 since 1996. Of 401 ICC cases diagnosed in 1991–2008 in 
Nijmegen, 11% were diagnosed in women younger, and 22% older, than the target 
cohort (de Bie et al. 2011). Another 40% were not screened in the last five years, 
21% had potentially false-negative tests, and the remaining 6% were screened as 
abnormal but follow-up or treatment had failed. Diagnostic smears were marked at 
registration and excluded from the study. Another Dutch audit analysed 2,074 cases 
of ICC, with 12% diagnosed before screening started and 20% at older ages than the 
target cohort and more than six years after last invitation (Bos et al. 2006). In this 
study only 19% had a preventive screening test in the last six years before diagnosis.
The Swedish audit used well-defined screening histories for 1,230 cases diag-
nosed in 1999–2001 and their age-matched controls (Andrae et al. 2008). National 
registers for cancer and screening episodes were linked with personal identifiers, 
ensuring high coverage and quality of data. Tests made within six months of di-
agnosis were considered diagnostic and excluded from the screening history. The 
proportion of cases with a negative screening test during the two screening rounds 
(six years) before diagnosis was 24%, and a further 11% had abnormal smears with or 
without biopsy, for at total of 36% with a history of screening. The presumed mode 
of detection was also reported, with 25% of cases being screen-detected. Another 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































all 187 ICCs diagnosed in the city of Malmö between 1991 and 2000 (Lindqvist et 
al. 2008). There were 72 cancers among participants and, in addition, 16 women 
had declined further management after abnormal cytology, for, in all, 47% interval 
cancers. The screening results were not comprehensively reported, but 21% of all 
cases were classified as misread as normal in the smear review.
In New South Wales, 877 invasive cancers, in total, were diagnosed in 2000–
2003 at ages of 20–69 (Yang et al. 2008). Each case was matched with three 
controls by month and year of birth. Goodquality registers of population, cancers, 
and screening tests were linked by means of probabilistic linking software using a 
number of non-unique personal data items. By screening history in the last four 
years, 66% of the cases were those of non-participants, compared with 13% of the 
controls. Pap tests of up to three months before diagnosis were excluded from the 
analysis. The authors recommend efforts to increase participation.
The practical conclusion of the failure analysis in nearly all of the studies re-
viewed was that increasing participation in screening offers the best potential for 
improving the effectiveness of the programme.
Studies including case–control analysis of the association between screening 
history and cervical cancer generally specified the derivation of screening exposure 
in greater detail. This involved mainly the precise and uniform definition of the pe-
riod of screening history under observation and the exclusion of diagnostic smears.
It has been proposed that effective screening for cervical cancer leads to declining 
proportions of squamous-cell cancers in the screened populations, and this has been 
observed in the cervical cancer trends in many countries with efficient screening 
programmes (Finnish Cancer Registry 2011). A slight but non-significant trend of a 
decrease in SCC as a proportion of total cancers detected in regions and countries 
with presumably fairly well-established screening programmes was observed over 
time across the audit studies discussed (see Figure 1A).
The trends over time of interval cancers, according to the definition in Table 
1, and interval cancers with a negative last smear reported in the studies listed in 
Table 2 are shown in Figure 1 (B–C). Even though declining trends are observed, 
neither measure shows statistically significant progress over time, possibly due to 
scattering, as the individual data points are derived from very different settings. 
In addition, the proportion of interval cancers depends not only on the effective-
ness of the intervention itself but also on, for instance, the coverage of the at-risk 
population by the screening programme. On average, coverage has expanded over 
time, which may counteract the effects of improvements in screening intervention 
effectiveness on the proportion of interval cancers.
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intervention itself but also on, for instance, the coverage of the at-risk population by the screening 
programme. On average, coverage has expanded over time, which may counteract the effects of 
improvements in screening intervention effectiveness on the proportion of interval cancers. 
 
 
   
   
 
Figure 1. Proportions of SCC (A), interval cancers (B), and cases with a negative screening before diagnosis (C) 
out of all diagnosed cervical cancers, and the proportion of analytical false-negative smears out (D) of all 
reviewed negative smears preceding diagnosis, over average year of diagnosis in the study population. Linear 
regression coefficients, with the associated 95% CI and p value of the observed trends, are indicated. 
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β= -0.003 (-0.011 to 0.004), p=0.390
figure 1. Proportions of SCC (A), interval cancers (B), and cases with a negative screening before diagnosis 
(C) out of all diagnosed cervical cancers, and the proportion of analytical false-negative smears out (D) of 
all reviewed negative smears preceding diagnosis, over average year of diagnosis in the study population. 
Linear regression coefficients, with the associated 95% CI and p value of the observed trends, are indicated.
6.3.3 audit of Cytology
The audit of cytology is concerned with those interval cancers that are preceded by 
a negative (or borderline) screening test (see Table 1). All negative screening tests 
in the preceding interval are potential false negatives. If the negative test result is 
confirmed in the review, the failure is due to either non-representative sampling 
or an incompatibility of screening test, test interval, and natural history of the 
specific case. It has been suggested that some cervical cancers may develop very 
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rapidly, such that one usually sufficient screening interval can encompass the whole 
development process from undetectable or absent disease to full-blown invasion 
(Austin and Zhao 2012).
Table 3 summarises cytological audit studies that are concerned with the sen-
sitivity of the screening test, define potential false negatives as negative screening 
tests within a specified time window before diagnosis, and include ICCs or SCCs 
with or without microinvasive carcinomas in the base population. The false-negative 
proportion shows high variability between studies with review of negative (Pap I) 
smears (21–71%). Some improvement in the quality of cytology over time by this 
measure was observed, but the trend was not significant in linear regression (see 
Figure 1, pane D). The proportion of clearly positive (warranting referral for colpos-
copy) false negatives was less variable and ranged from 14% to 31% in the studies 
that did not include Pap II smears in the review. Usually, not all archive smears 
representing potential false-negative screening tests in a study can be located; for 
this reason, the denominator used for the false-negative proportion in the table is the 
number of negative smears reviewed and not the total number of cases in the audit.
One of the first studies that elegantly described the screening history and false-
negative proportions of cervical cancer cases was that by Eva Rylander, with 177 
cases diagnosed in 1968–1974 in Stockholm. Out of 69 negative smears four to five 
years prior to detection of cancer, 56 were retrieved for review. The review was done 
blinded with negative control samples from women without subsequent cancer 
diagnosis. Twenty-one of the smears reviewed were confirmed as negative, and 35 
(63%) were judged atypical at presentation. This study also observed that interval 
cancers after negative smears were more frequent in younger women than among 
older women. The false-negative proportion was not presented by age, unfortunately.
An Australian report from Victoria audited 1,044 incident cases of cervical can-
cer of women aged under 70 (Mitchell et al. 1990). There were 156 negative cer-
vical smears reported for the 36 months before the diagnosis of cancer, and 143 
were obtained for review by a senior scientist and a cytopathologist. No controls 
were used. Seven smears (5%) were considered unsatisfactory for analysis, 21% 
had changes less than indicative of CIN, 31% showed changes indicative of CIN, 
and 43% were confirmed negative.
Kristensen et al. (1991) reported screening histories of 376 women from Funen, 
Denmark, who were diagnosed with cervical cancer in 1979–1983. Of these, 202 
had smears taken within three years prior to diagnosis, with a total of 355 smears. 
No controls or blinding was used in the review. Of the 96 potentially false-negative 
smears, 57% were confirmed negative, 2% inadequate, and 18% atypical, and 23% 
were upgraded to CIN or cancer, for a false-negative proportion of 43%. A more 
recent study from Copenhagen described the results of a quality-control audit of 112 
cancer cases diagnosed in 2008–2009 (Kirschner et al. 2011). There were 56 cases 
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with a regular screening history 5.5 years prior to the diagnosis of cancer, and 11 
of the cases (20%) had smears reviewed as HSIL or worse. There was no mention 
of lower-grade atypical findings, which would presumably elevate the estimate if 
reported. No controls were used in this review.
In Canada, the screening programme in British Columbia was one of the earli-
est effectively organised programmes in the world (Fidler et al. 1968). A study of 
screening histories of 437 invasive cancer cases diagnosed in 1985–1988 reviewed 
all 116 negative smears in the screening files preceding diagnosis (Anderson et al. 
1992). The review process was not described with respect to the number of review-
ers, any controls, and blinding. False negatives, defined as missed abnormal cells, 
numbered 39 out of the 116 originally negative smears. There were 64 cases with 
negative smears within three years of diagnosis, and the authors stated that the 
false negatives were usually seen in this group, without reporting numbers. An-
other Canadian study reported screening histories for 246 invasive cancer cases 
diagnosed in Alberta in 1990–1991 (Stuart et al. 1997). In this study, several inde-
pendent evaluations were used, with final cytology resolved by consensus of three 
pathologists. Controls and blinding were also used, to reduce observer bias. There 
were 170 smears with normal or benign (below ASC-US) results in the original 
analysis, and 93 (55%) of these were ASC-US or worse or were deemed unsuitable 
for interpretation at review. Review results requiring referral were recorded in 42 
(25%) of the cases.
A review of negative cytology preceding frankly invasive cancers diagnosed in 
Northern Ireland in 1965–1989 found 139 negative smears from 103 patients up 
to 12 years before diagnosis (Robertson and Woodend 1993). The review was per-
formed by the two authors independently, without controls. There were 92 smears 
with dyskaryotic cells (66%) and 67 out of 95 (71%) within five years of diagnosis.
One of the few audits concerned with cases of cervical cancer death is from 
the UK. It reviewed negative smears preceding the diagnosis of cervical cancers 
in Rotherham (Slater et al. 1994). There is no mention of blinding in the report. 
There were nine cases out of 36 with a true-negative last smear in the period ex-
amined (eight years prior to diagnosis) and five with a false-negative last smear 
(36% false-negative proportion). Three of these five were considered inadequate 
upon review, leaving two that were upgraded to positive samples (14% of the po-
tential false negatives).
One large – if not the largest to date – published cytology audit used data from 
the cervical screening programme in England, with 6,113 cases of invasive carci-
noma of the cervix diagnosed between April 2007 and March 2010 (Castañon et 
al. 2012). In total, 7,621 cytology samples taken within 10 years of diagnosis were 
reviewed, and 3,759 of these were potential false-negative screening tests. The re-
view confirmed the negative result for 45% of these samples, 11% were deemed 
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inadequate for analysis, 18% were borderline, and 25% were clearly positive. There 
was no blinding of reviewers to the original results or the fact that the patient was 
subsequently diagnosed with cancer. This may have elevated the analytical false-
negative rate observed. In fact, given that, of all studies reviewed, this one involved 
the longest time between sample and cancer diagnosis, the false-negative rate seems 
somewhat higher than expected. There were also 644 borderline samples in the 
review, of which 65% were deemed clearly positive upon review. Another British, 
welldescribed audit summary, from the Southampton area, presents review results 
for 73 negative slides taken up to 5.5 years before diagnosis (Herbert et al. 2009a). 
Of the potential false-negative slides, 11% were reviewed as inadequate, 17% as low-
grade dyskaryosis, and 31% as high-grade dyskaryosis.
The only study in this overview from the US audited 664 cervical cancer cases 
diagnosed in Connecticut from March 1985 through February 1990 (Janerich et al. 
1995). In all, 137 negative smears were obtained for review, and 29 (21%) of these 
were classified as ‘misread as normal’ on the basis of ‘some evidence of dysplasia 
or premalignant abnormalities’. The review was performed without controls by two 
cytopathologists who were blinded to the screening history.
Kenter et al. (1996) reported audit results for 306 out of 469 patients diagnosed 
with SCC in 12 hospitals in the western part of the Netherlands in 1980–1989. All 
previous smears were reviewed with blinding to the original cytology, but no controls 
were used. There were 39 Pap I/II screening tests within 3.5 years of diagnosis, 
and 53% of these were considered a false negative, defined as a result requiring 
immediate referral. The remainder consisted of Pap II and inadequate smears upon 
review, and no smears were confirmed negative. In a later Dutch study, 401 inva-
sive cervical cancers diagnosed between 1991 and 2008 at a hospital in Nijmegen 
were audited (de Bie et al. 2011). There were 85 patients with smears ‘within nega-
tive limits’ in the five years before diagnosis. No controls were used in the review, 
which confirmed negative results in 39% of cases, considered 24% unsatisfactory 
for analysis, deemed 18% ASC-US or LSIL, and found 19% to be HSIL or worse.
The Slovenian organised cervical screening programme was launched in 2003, 
and a cytological audit study of the 162 cervical cancer cases diagnosed in 2006 
was published recently (Repše-Fokter et al. 2012). There were 34 normal smears by 
original cytology recorded in the three years prior to diagnosis, and eight of these 
were upgraded in a blinded review with controls, for a false-negative proportion of 











































































































































































































































































































































































































































































































































































































































































































































Length of retrospective follow-up was analysed as an explanatory variable for 
the differences in false-negative proportions, but no correlation was found in this 
collection of audit studies. Neither did the use of controls appreciably explain the 
variability. The unweighted-average false-negative proportion reported in studies 
using controls in the review was 47%, as compared with 52% in the studies not using 
them. The corresponding averages weighted for number of smears reviewed were 
52% and 54%. It is tempting to conclude that the differences seen in the false-nega-
tive rates really do reflect differences in the sensitivity of cytology between settings. 
Many of the studies describing cytological audits of potentially false-negative 
smears were not reviewed here, because of attempts to keep the included studies 
comparable. The majority of the ineligible studies did not specify the interval be-
tween smear and diagnosis. An open-ended retrospective screening history pro-
vides more potential false-negative smears for review, but the exact length of time 
before diagnosis can be important for failure analysis. When the period examined 
before diagnosis becomes more than one or two screening intervals, the propor-
tion of true negatives should be progressively higher and the significance of the 
results may diminish.
6.3.4 audit of histopathology
There are only a few studies that audit histopathology. While histopathology is 
often seen as a gold standard for screening-test validity studies, it can have valid-
ity problems of its own. The recent Danish audit study included review of nega-
tive histopathology slides and found two cases of false negativity in an audit case 
population of 112 (Kirschner et al. 2011). The number of potential false negatives 
reviewed was not reported. The large UK audit by Castañon et al. (2012) reviewed 
all histopathology specimens of the audited cancer cases, regardless of original diag-
nosis. Of 112 originally normal histological samples reviewed, 66% were confirmed 
normal in review, 13% were inadequate, and 16% were upgraded to intraepithelial 
neoplasia and 5% to invasive carcinoma. So with the strictest definition of a false 
negative, 34% of the histopathological diagnoses audited were false negative, as 
compared with the 55% for cytology false negatives in the same study. Reviews 
of histopathology should be included in the audit of cervical cancers, especially if 
screening history indicates that interval cancers occur after a negative colposcopy.
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6.4 outCome-based evaluation of sCreening  
 programmes
6.4.1 methodology
The screening history of case series alone cannot answer questions as to the ef-
fectiveness of the programme, or loss of effectiveness due to a specific category of 
failure. The proportion of failure categories such as subsequent (within-interval or 
at-next-screen) cancers in the population will depend on the effectiveness of the 
screening service but also on the coverage of the programme. For this reason, it 
becomes necessary to include controls without cervical cancer in the analysis of 
screening histories when attempting to answer questions specifically about effec-
tiveness and preventable percentages. Also, full case–cohort information would be 
appropriate, even though such analyses would require considerable resources for 
tracing all of the details in the screening history among non-cases; therefore, such 
designs are not considered here. 
In case–control evaluations, it is important to pay close attention to the selection 
of cases and controls, the definition of exposure, and the handling of bias (Cronin 
et al. 1998). Specific concerns include inclusion of all case subjects within a source 
population, definition of eligibility criteria in a manner ensuring that the case and 
control subjects had equal access to screening during the exposure period, the dis-
tinction between symptomatic and screening smears, handling of screendetected 
cases of invasive cancer, and control of self-selection bias (Moss 1991, Cronin et 
al. 1998).
The case subjects should have a manifestation of disease that develops only after 
the preclinical stage of disease (Morrison 1982). In cervical cancer screening, this 
can be interpreted as meaning either fully invasive carcinoma of FIGO stage IB and 
above or, alternatively, any invasive carcinoma, which includes also stage IA. The 
argument against including microinvasive (IA) carcinomas in the endpoint defini-
tion is that they usually do not cause any symptoms and hence can be classified 
as falling under the preclinical stage of disease. On the other hand, if the aims of 
screening include the prevention of any invasive carcinoma of the cervix, all stages 
of invasive disease should be included in the evaluation, for a complete overview 
of effectiveness. One can use endpoints of later stages – for example, cancers that 
cause death. In evaluation of recently commenced screening programmes, cases 
occurring soon after initiation should be excluded, because full screening benefits 
would not be expected for several years (Moss 1991). This is especially important 
if the outcome is mortality.
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Controls should be drawn from the source population of the cases. Control 
subjects are usually matched to the cases with respect to age, place of residence, 
and sometimes also socio-economic status. The matching is an attempt to equalise 
differences in factors that are associated with both exposure and risk of disease. 
Stratified analysis by age can be an alternative to matching.
If the aim is to evaluate the preventive effect of screening, all screening tests, 
both negative and positive, must be counted toward exposure. Tests done because 
of symptoms and true screening tests should also be distinguished. This can be 
problematic in programmes that are not based on invitation on a fixed date. In 
addition, tests leading to diagnosis should be disregarded, as they cannot confer 
any preventive effect. Many case–control studies exclude a period of 6–12 months 
before diagnosis in order to rule out diagnostic tests. This can cause an unpredict-
ably directed bias of its own (Weiss 1998, Zappa and Ciatto 2000).
Many methodological problems are reduced in settings wherein there is a cen-
tralised (organised) screening programme with active invitation at fixed dates; ac-
cess to complete registers of cancers, invitations, and screening details; and a well-
established (i.e., not recently initiated) screening programme (Zappa and Ciatto 
2000). In this situation, tests done because of symptoms are not mistaken for 
screening tests, there is no recollection bias, and screening will have been avail-
able during the pre-invasive phase, when screening for cervical lesions can have a 
preventive impact.
Even in optimal conditions, there remains, however, the issue of self-selection 
bias. This arises from the response to invitation being an active choice influenced 
by personal characteristics, some of which may also influence the risk of cancer. 
Subjects are in this case self-selected into participants and non-participants with 
different baseline risks, regardless of any effect of the exposure itself. Self-selection 
bias is notoriously difficult to quantify in established long-running screening pro-
grammes with no easily available reference population without exposure to screening 
invitation. Collection of potential confounder information related to lifestyle and 
socio-economic status has been used to control this bias, but the resulting adjust-
ments have usually been small, and in any case these data are typically not avail-
able in register-based studies (Kasinpila et al. 2011). Another approach has been 
to measure the risk ratio for other types of cancers and assume it to indicate the 
magnitude of the self-selection bias also affecting the risk of cervical cancer (Ak-
limunnessa et al. 2006). Unfortunately, there is no evidence of the validity of this 
assumption. There are some indications of the magnitude of this bias from early 
cohort studies wherein unscreened populations were used for comparison. When 
organised screening programmes were started, it was possible to draw expected 
cancer rates from the time before screening; doing this, Fidler et al. (1968) found 
a relative risk of 1.08 for those unscreened in the programme even though it is un-
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clear how active their self-selection was – i.e., whether there was equal opportunity 
to participate. On the basis of early data from the Finnish screening programme, a 
relative risk of 1.6 was observed for those unscreened in the invitational programme 
(Hakama and Räsänen-Virtanen 1976). A third cohort study utilised expected cancer 
incidence rates drawn from neighbouring regions without screening programmes 
for a relative risk of 1.61 for invited non-participants (Magnus et al. 1987).
6.4.2 Case–Control studies of effeCtiveness 
Previous summaries of case–control evaluations of cervical cancer screening include 
the IARC collaborative study (IARC 1986) that consisted of a collection of studies 
assessing the association of cervical cancer risk and negative results in cervical 
cytology tests from Europe and North America. At least two later summaries are 
available (Zappa and Ciatto 2000, IARC 2005). This section of the chapter is based 
on a search of the literature for case–control evaluations of cervical screening pub-
lished in 1990 or later with exposure based on both negative and positive smears. 
Sixteen such studies were identified and are listed in Table 4.
The first case–control evaluation published in this period included women un-
der 75 with a diagnosis of cervical cancer in 1982–1985 and age-matched controls 
from Florence, Italy (Palli et al. 1990). Exposure was determined via interview 
of subjects and, in cases of death, through relatives whenever possible. Exposure 
was defined as ever versus never, excluding the last six months before diagnosis. 
Reported crude OR was 0.20. After adjustment for socio-economic factors, the OR 
estimate was 0.15. Recollection bias could be an issue with this study. 
A study from Scotland determined the screening exposure prior to diagnosis 
and prior to smears leading to diagnosis of cervical cancer cases and deaths, and 
screening-register-based controls (Macgregor et al. 1994). Controls were matched 
for age and for having a negative smear at the date of presentation of the case. An 
OR of 0.67 was seen for incidence of screening exposure within three years. Effect 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   




































































































































































































   
   





























































































































   






























































































































































   
























































































































































































































































































































































































































































































All 179 cases of invasive cervical cancer treated at a Finnish hospital in 1987–
1994 and alive in 1994 were classified according to their exposure to organised 
screening, spontaneous screening, and gynaecological visits (Nieminen et al. 1999). 
Controls from the hospital catchment area were sampled from the population 
register, along with socio-economic data for both cases and controls. Exposure 
and risk factors were derived through questionnaire. The exposure window was 
closed the year before diagnosis. The ORs for ever- versus never-screened were 
adjusted for 10-year age groups. The ORs were also adjusted for the other two 
types of exposure. An OR of 0.38 was reported for organised screening, while the 
effect estimate was smaller for spontaneous screening (OR: 0.82). There is a pos-
sibility of exposure misclassification and selection bias, although this should not 
affect the striking difference in effect seen between the two modalities of screen-
ing. Cases were restricted to those patients who had not died from their cancer, 
and it is possible that effect estimates for this population are smaller than among 
all diagnosed cases.
A Swedish study included all 112 cervical carcinoma cases diagnosed at a hospital 
in Karlstad (Andersson-Ellström et al. 2000). The screening histories were derived 
from cytology registers and compared with population-based controls matched 
by age. A Chi-square test was used to compare proportions of smears 1–3 or 3–6 
years prior to diagnosis. The extracted crude OR was 0.81 over all ages for screen-
ing within three years.
In countries with a less developed health infrastructure, evaluation results can 
nevertheless be promising and long-lasting risk reductions observed, but these re-
sults should be interpreted with caution. In South Africa, a hospital-based study 
with 524 stage-IB+ ICCs and series-matched controls found that the association of 
Pap smears more than 15 years previously between the risk of cervical cancer was 
significant (OR: 0.5, 95% CI: 0.4–0.7) (Hoffman et al. 2003). In this study, data 
on several risk factors were collected and adjusted for by means of unconditional 
multiple logistic regression in order to limit the effects of self-selection bias, but 
the magnitude and duration of the effect of screening suggest that this was prob-
ably not entirely successful. In addition, screening history was based on interview, 
wherein recollections of events decades past were used as exposure information. 
A real risk of misclassification bias is present. The authors refer to a publication 
in Latin America that compared screening histories for newly diagnosed cases of 
cervical cancer in four hospitals in four countries with those of age-matched hos-
pital or community controls (Herrero et al. 1992), as an example of good effect 
in developing countries. The Latin American study excluded 12 months prior to 
diagnosis and found the protective effect to increase with age from an OR of 0.56 
for ages under 30 at diagnosis to 0.25 for ages 40–49. Similar risk reductions were 
observed for adenocarcinoma (OR: 0.50), which could indicate a significant com-
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ponent of bias in the estimates. Exposure was defined by interview, which could 
lead to misclassification, and selection bias may be a major issue. Another study, 
with 397 invasive cases diagnosed at six hospitals in Mexico City and population-
based controls stratified by age, also used interviews to determine ever-versus-never 
screening status with exclusion of the last year before diagnosis (Hernandéz-Avila 
et al. 1998). Estimates were adjusted for age, socio-economic status, and sexual 
history. When diagnostic smears were factored out, an OR of 0.38 was observed 
(without this distinction, the OR was 0.76).
Sasieni et al. (2003) investigated primarily the length of the protective – or, 
in fact, selective – effect of a negative screening test with different age groups but 
reported also conditional logistic regression results for having an adequate screen-
ing test within specific one-year intervals before diagnosis in different age bands, 
ignoring all smears within six months of diagnosis. Screen-detected cancers could 
not be identified in this study, but all microinvasive carcinomas were excluded. Cases 
were diagnosed in 1990–2001. Compared with those without any adequate screens 
registered, the ORs of cervical cancer for those 20–39-year-olds with their last 
but not only screen 0.5–1.5, 1.5–2.5, and 2.5–3.5 years before diagnosis varied 
between 0.35 (0.23–0.54) and 0.77 (0.53–1.11). For 40- to 54-year-olds, the ORs 
varied between 0.22 (0.14–0.34) and 0.38 (0.26–0.54) and for 55–69-year-
old women between 0.18 (0.11–0.30) and 0.42 (0.27–0.65). An earlier UK study 
defined screening histories for cases of cancer diagnosed in 1992 in participating 
districts and for age-matched community-based controls (Sasieni et al. 1996). The 
main result again was risk reduction by time after negative smear, but all smears 
were reported such that a crude OR of 0.52 can be extracted for stage-1B+ cancers. 
Screening registers were used to determine exposure six months to five years before 
diagnosis for women under 70.
In Trento, Italy, age- and morphology-specific case–control analysis produced 
high effect estimates for adenocarcinoma also (Crocetti et al. 2007). The study 
identified all cervical cancers diagnosed at the ages of 25–74 in 1995–2000 but 
excluded microinvasive carcinomas and cases among women resident in the region 
for less than five years. Controls were matched by age to their cases, had to be alive 
at the time of diagnosis, and also were residents for the past five years. Screening 
tests done less than 12 months before diagnosis were excluded from exposure. 
High effect estimates were found for tests performed 1–3 years before diagnosis. 
For example, an effect of 96% was observed for invasive cancer in the age range 
40–59. The overall protective effect for adenocarcinoma too was high (OR: 0.24). 
The effect of screening women under 40 was smaller and non-significant (OR: 
0.50, 95% CI: 0.70–3.62). Possible biases affecting the findings of this study are 
caused by the exclusion of 12 months’ screening history in a relatively short ex-
posure window (three years) and self-selection.
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The same selection criteria for cases, controls, and screening history were used 
in another Italian study (Zappa et al. 2004). Here the effect on the risk of SCC was 
of the same magnitude (OR: 0.15) for women 40 or over, but a clear effect was also 
observed for women under 40 (OR: 0.16). Effect estimates for adenocarcinoma were 
not significant. Estimates were adjusted for civil status and place of birth, but crude 
estimates were not reported. The authors discuss the possibility of residual bias 
but again argue that comparisons of age groups and histological types of cancers 
should not be affected even if absolute effects are overestimated. 
A register-based study from Odense, Denmark, analysed the screening histories 
prior to diagnosis of 67 women who died of cervical cancer and 67 population-based 
age-matched controls (Ejersbo 2008). Dichotomous screening history determinants 
as to ever or never screened, more than two screening tests recorded, and any 
screening tests within five years of diagnosis were reported. Diagnostic smears were 
excluded, with this classification based on hospital records. Results were presented 
as numbers and proportions, so the odds ratios in Table 4 are crude odds extracted 
from the available counts. Estimates were different in the two age groups: women 
up to 59 and 60 or over. The odds ratios were 0.25 for the younger women and 
0.87 for the older women, with an overall OR of 0.54.
An Australian study from New South Wales evaluated the association with 
screening tests four years before diagnosis (Yang et al. 2008). Tests performed 
within three months of diagnosis were excluded from the screening history. Expo-
sure was categorised into no screening, irregular screening (that is, one screening 
event within the window of exposure), and regular screening (biennial, as recom-
mended). Very high protective effects for all invasive cervical cancers were observed, 
and odds ratios did not vary by age. However, controls were drawn from the screen-
ing register, which may introduce a strong bias in favour of screening if coverage is 
not complete. Furthermore, protective-effect estimates for non-squamous cancers 
were also very high (up to 93%) and did not differ significantly from those for squa-
mous carcinomas. This may be an indication of a large selection-bias component.
A very large study from the UK, with 4,012 women aged 20–69, investigated 
the effect of screening participation in overlapping three-year bands on the cervi-
cal cancer risk in the following five-year period (Sasieni et al. 2009b). Protective 
effects of 60–80% were estimated for cervical cancer in women at ages of 40 or 
more, but there was considerable age-dependency of effectiveness, with screening 
under the age of 25 having little or no effect. The main potential bias remaining 
in this study is self-selection bias. For the difference in effect for different ages to 
be invalid, however, the selection bias would have to be age-specific. The authors 
argue that this is unlikely and unsupported by evidence.
A nationwide cervical cancer screening programme with recommended every-
five-year cytology screening tests for women of ages 35–60 was started in 2005 
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in Thailand. The effectiveness of the programme was evaluated by investigation of 
screening histories of 130 (out of 135 invited to participate in the study) women 
with ICC, treated in four clinics in north-east Thailand (Kasinpila et al. 2011). Two 
control groups were recruited, with frequency-matching by age: 130 hospital con-
trols from other wards and 130 presumably healthy hospital companion controls. 
There were no significant differences in risk factors or screening history between 
the two control groups, so they were combined for the final analysis. Data on risk 
factors known to be associated with both screening history and cancer were col-
lected by interview. Socio-economic markers were strongly associated with cancer 
risk, but in a multivariate analysis the only significant variables were alcohol con-
sumption, age at first intercourse, and the use of oral contraception. Adjustment 
for these variables did not make a large difference for the effect estimates. The ef-
fect of screening 6–11 months before diagnosis was estimated at 1.38, which may 
indicate that there were still diagnostic tests within this period. Screening 1–2 full 
years before diagnosis was associated with an adjusted relative risk of 0.27, and 
the relative risk was 0.42 with an interval of three years or more. However, as the 
study was based on interview, there is a risk of recall and misclassification bias. 
Tests done because of symptoms and those leading to the detection of cancer could 
not be directly identified in this study, but the final analysis of screening history 
did exclude those smears taken within six months of diagnosis. This approach is 
widely used but carries a risk of overestimating the screening effect (Weiss 1998). 
The authors discuss the possibility of residual confounding and, especially, the 
potential effect of unmeasured self-selection bias and conclude that the effect esti-
mates probably are too optimistic.
Earlier studies often defined screening exposure in terms of ever- versus never-
screened. All studies done after 2000 define screening history in a specific window 
of exposure, usually related to the recommended screening interval (but not nec-
essarily coinciding with the duration of protection). In general, later studies have 
also included more detailed descriptions of the methodology employed. A gradual 
shift over time toward conditional logistic regression was noted in the statistical 
analysis methods. Many studies with large effects were vulnerable to misclassifi-
cation of exposure due to a lack of administrative registers, and also the inclusion 
of all relevant outcome events may have been suboptimal. Most studies did not 
demonstrate good means of discriminating between diagnostic and screening tests, 
or screen-detected and symptomatic cancers, and had to resort to restriction of the 
window of exposure, which brings a risk of bias. None of the studies had the ability 
to correct for selfselection bias directly; adjustment for risk factors was employed 
in some instances, but the effect on estimates was small when reported.
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6.5 advanCes in bioteChnology – improved test  
 sensitivity and primary prevention
6.5.1 hpv testing
Despite the impressive track record of cytology, some features have been objects 
of criticism. The sensitivity of a single smear for intraepithelial lesions can be low 
and variable. Cross-sectional sensitivities ranging from 30% to 87% have been re-
ported for a test threshold of LSIL and a disease threshold of CIN1, and from 44% 
to 99% for a disease threshold of CIN2 with specificities of 91% to 98% for CIN2+ 
(Nanda et al. 2000). However, in practice, repeated smears during the long period 
of preclinical lesion development ensure that compounded programme sensitivity 
is higher. The compounded programme sensitivity benefits not only from several 
tests being done over the lifetime of preclinical lesions but also from the fact that 
some of the lesions missed during one screening episode will regress in the inter-
val before the next screening round. Another important and related drawback is 
the poor inter-observer and also intra-observer reproducibility of results, which 
is due to the subjective evaluation of cytopathology, the quality of which, in turn, 
is highly dependent on the level of training and experience of the laboratory staff 
(Stoler and Schiffman 2001).
Screening based on primary HPV DNA testing can offer improved performance 
in these areas: HPV testing has a relatively high sensitivity for precancerous le-
sions; good reproducibility of test results; and, naturally, also a high specificity for 
HPV disease (Ronco et al. 2010a). On the other hand, specificity for higher-grade 
lesions (CIN2+, CIN3+) is lower. This becomes a problem at younger ages, when 
HPV infections are prevalent but progression to cervical cancer is rare. For this 
reason, primary HPV DNA testing can only be recommended for women aged 30 
and above (Schiffman et al. 2010).
HPV testing can be based on the detection of viral DNA, mRNA, or viral proteins. 
Most screening programmes use DNA-based diagnostic test systems. There are two 
main types of tests for the detection of HPV DNA. The most widely used tests are 
nucleic acid hybridisation assays for collective detection of 13 high-risk types of HPV 
viruses (Cuzick et al. 2008). In addition, tests based on the polymerase chain reaction 
are available (Gravitt et al. 2008). RNA-based tests are an attempt to increase the 
specificity of HPV tests by detecting the presence of transcripted messenger RNA of 
viral oncoproteins. The rationale is that active oncoprotein production in infected 
cells is more prognostic of progressive neoplasia than is the presence of viral DNA. 
The main oncoprotein mRNAs of interest are E6 and E7 (Andersson et al. 2012).
Another approach is the detection of tumour suppressor gene products (Brown 
et al. 2012). Normally the cell cycle is carefully regulated, and mitosis usually in-
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creases the expression of the p16 gene, which, in turn, represses further cell replica-
tion. The E7 HPV oncoprotein inhibits the function of the p16 gene product, which 
leads to over-expression of p16. Immunocytochemical detection of the resulting 
high concentrations of the p16 product is possible either in cytological or in histo-
logical samples, but the method still suffers from non-standardised interpretation 
and poor reproducibility (Tsoumpou et al. 2009, von Knebel Doeberitz et al. 2012).
There are also methods available for direct detection of the viral oncoproteins 
E6 and E7, but there is little experience or information available with respect to 
the performance of these tests in screening applications (Laurenson et al. 2011).
HPV screening based on the detection of DNA is a viable alternative in low-
resource settings if the laboratory infrastructure and experience needed for reliable 
cytology are lacking (Sankaranarayanan et al. 2009). With automated analysis of 
HPV DNA tests, it is easier to achieve high and consistent performance. HPV tests 
may bring improvements even in settings with good-quality cytology, thanks to 
increased sensitivity and a long-lasting NPV, but this requires that the screening 
protocol be appropriately chosen and that the benefit-to-harm ratio be rigorously 
evaluated and monitored (de Kok et al. 2012).
6.5.2 vaCCines
There are currently two commercial prophylactic HPV vaccines available, and both 
are used in national vaccination programmes. They confer high immunity against 
new infection with HPV types 16 and 18, and one contains, in addition, antigens 
from low-risk types 6 and 11, which are the most important causative agents for 
genital condyloma (Einstein et al. 2011).
Prophylactic vaccines may have the potential to answer the challenge of possi-
ble lower screening effectiveness in the younger age groups, under 30 (Brotherton 
et al. 2011). When the vaccinated cohorts reach the core screening ages, 30–64, 
there will probably also be impacts on the optimal configuration of the screening 
programmes. Vigilant monitoring and evaluation is, therefore, especially vital in 
the coming years, because of these near-future challenges and opportunities of 
cervical cancer prevention. Vaccinated and unvaccinated cohorts should be audited 
separately, since there may be a need to provide separate screening programme 
protocols according to vaccination status (Lehtinen et al. 2012).
Therapeutic vaccines are under development, and these may affect treatment 
options and follow-up (Barrios and Celis 2012). If these vaccines have long-lasting 
immunological effects, there may also be consequences for the optimal screening 
algorithm for treated women.
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7 aims of the study
The aim of this study was to evaluate performance and age-specific effectiveness of 
cervical cancer screening, by focusing on audit studies examining the Finnish cervical 
cancer screening programme within case–control designs wherein information 
on the outcome of screening was taken into account. 
The study also developed further quality assurance protocols for integration 
into the programme. More detail-level research problems included assessment of 
the quality of the screening monitoring database, auditing of test performance and 
validity in the screening programme, and evaluation and auditing of the effects of 
the cervical cancer screening programme on cervical cancer in an agespecific man-
ner. Specific studies included the following:
1. Evaluation of the completeness and accuracy of outcomes (cervical pre-
cancerous lesions and cancer) recorded in the cervical cancer screening 
register, by comparing data with both the cancer register and the admin-
istrative hospital discharge register
2. Evaluation of the performance and validity – specifically, the false-negative 
rate, sensitivity, specificity, and reproducibility – of the cytological screen-
ing test in an outcome-based audit of cytology within the programme
3. Evaluation of variation in cross-sectional performance indicators by screen-
ing laboratory and the assessment of any association with longitudinal 
sensitivity
4. Audit of screening histories of cervical cancers and controls so as to identify 
areas of potential for improvement within the screening policy and service. 
Particular emphasis was given to evaluating the effect of one screening epi-
sode at a given age in the programme against cervical cancer and cervical 
cancer death. Any variation in effectiveness across age at invitation was 
studied, with particular attention to the marginal age groups of 25 and 65, 
which are currently not recommended but merit further consideration in 
terms of whether they should be targeted by the programme
The output from these evaluations is essential for producing information needed 
to support decision-making on programme modifications and for developing feed-
back to the screening service providers.
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8 materials and methods
8.1 the CerviCal CanCer sCreening programme in  
 finland
Cervical cancer screening was introduced in 1963 as a regional pilot programme 
and expanded to national coverage by 1970 (Anttila and Nieminen 2000, Anttila 
and Nieminen 2007). The Government Decree on Screenings (1339/2006) speci-
fies that municipalities shall organise fiveyearly screening tests for cervical cancer, 
starting at the age of 30, with the last invitation issued at 60. All women in the 
targeted birth cohorts are sent a personal invitation to be screened. Nearly complete 
coverage of the recommended target age groups by invitations has been reached in 
recent years (see the unpublished results in Table 5). The coverage showed some 
regional variation in the ’90s, and a number of municipalities have also invited 
25- or 65-year-old women.
Table 5: Invitation coverage of the cervical screening programme in Finland in 1990–2009 (%)
Age 1990–1994 1995–1999 2000–2004 2005 2006 2007 2008 2009
25 40 32 36 35 28 30 29 15
30 70 74 89 93 92 94 98 98
35 92 92 98 98 98 99 99 100
40 98 99 99 99 99 100 100 100
45 98 95 97 99 99 100 100 100
50 98 99 100 100 99 100 100 100
55 79 91 97 98 96 98 100 100
60 59 76 88 95 94 97 99 99
65 12 15 16 16 15 16 16 3
Data source: Cervical cancer screening register at the Mass Screening Registry.
Invitation year
The screening test in use is conventional cytology, except in a number of mu-
nicipalities in Southern Finland that participate in a randomised public-health trial 
comparing primary HPV DNA screening to conventional cytology (Anttila et al. 
2006, Leinonen et al. 2009, Anttila et al. 2010). Borderline cytology (ASC-US, 
AGC-NOS according to Bethesda terminology (Solomon et al. 2002), or equivalent 
Pap II findings before year 2006) triggers a new, so-called risk-group invitation in 
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12 months instead of the five years in the default programme for screen negatives. 
LSIL or worse (LSIL+), or Pap III–V (before 2006), leads to immediate referral 
for colposcopy (Nieminen et al. 2010). Women with referral are actively followed, 
and data on the histological confirmation are collected by the screening laboratory 
and eventually registered in the screening database of the Mass Screening Registry.
8.2 data sourCes
Monitoring and evaluation of screening, as of other public-health interventions, are 
actions greatly facilitated by high-quality registers and the ability to link them at 
the level of the individual, preferably by means of a personal identifier. The Nor-
dic countries, Finland among them, have a long history of population registration 
and national registers for several aspects of health care, such as cancer screenings, 
birth, prescriptions, hospital discharge, health insurance payment, cardiovascular 
disease, and infectious disease. These can be used to explore associations of risk 
factors or interventions and outcomes at a low cost of additional resources. This 
study has utilised the cervical cancer screening database, the cancer register, and 
the administrative hospital discharge register as data sources.
8.2.1 the sCreening register
Complete, or nearly complete, individual-level data on the cervical cancer screening 
programme are currently available in the electronic database from 1963 to 1976 
and again from 1990 onward. For this study, data from 1990 to 2009 were used to 
construct screening histories for the study subjects. Relevant data included invita-
tion year, inviting municipality, type of invitation (age- or risk-based), screening 
laboratory, date and result of screening test, any follow-up recommendation, and 
date and result of histological verification.
8.2.2 the CanCer register
The histological verification, or diagnosis, data registered in the screening register 
are based mainly on the first colposcopy and biopsy after referral. For the cancer 
register, on the other hand, all cancer notifications from hospitals, physicians, and 
pathological and haematological laboratories and death certificates with cancer 
as a cause of death are reviewed before a summary, or synthesis, of all available 
information is registered. The result is a very complete and accurate register of 
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malignancies (Teppo et al. 1994). In addition to malignant neoplasms, the can-
cer register includes some premalignant conditions of the cervix uteri (the cervix 
uteri is represented by topography codes C53.0–C53.9 in the ICD-O-3 classification 
(Percy et al. 2000)). These are dysplasia gravis, which is not specified in ICD-O-3 
and therefore is registered with an in-house code; CIN3 with ICD-O-3 morphology 
code 8077/2, SCC in situ (CIS) (8070/2); carcinoma in situ NOS (8010/2); and 
AIS (8140/2). The classification of lesions into these categories has developed over 
time, and also there was clear under-registration of premalignant diagnoses until 
the late 1990s (Finnish Cancer Registry 2009).
Invasive cervical cancer can be separated into more than 40 morphological 
types, according to the WHO (IARC 2005). These can be grouped into SCCs, adeno-
carcinomas, and other specified and unspecified malignancies. The overwhelming 
majority of cervical malignancies derive from the epithelium, or, in other words, 
are carcinomas. In addition, a small number of sarcomas are located at the cervix. 
The SCCs are the most common type of cervical cancer, and they are also the type 
most effectively prevented by cytology screening (ibid.). Of all 1,548 cervical can-
cers diagnosed in Finland in 2000–2009, 62% were SCCs, 29% adenocarcinomas, 
4% other specified or unspecified carcinomas, 2% sarcomas, and 3% unspecified 
malignancies (see Table 6, from Paper IV and unpublished work). Out of the 545 
deaths from cervical cancers in 2000–2009, 61% were due to SCCs, 28% adeno-
carcinomas, 5% other or unspecified carcinomas, and 1% sarcomas, and 5% were 
caused by morphologically unspecified cervical malignancies.
The stage of disease registered in the FCR represents summary information de-
rived from all cancer notifications, whether clinical or pathological, and is divided 
into localised, locally spread, metastasised, and spread but to an unknown extent. 
This staging is applied to all cancer sites. However, the recommended staging for 
cervical cancer according to FIGO (Pecorelli et al. 2009) is the clinical stage at 
presentation, which represents the pre-surgical information that is available when 
treatment is planned. The clinical stage does not have the same predictive value 
with respect to survival as post-surgical, or pathological, staging, but it is never-
theless favoured because of comparability issues. We determined the clinical stage 
by going through the cancer notifications for cervical cancers diagnosed (IV) or 
cause of death (V) in 2000–2009 and were able to derive a clinical stage for 66% 
of these cases. Absence of clinical stage was complemented by pathological stage 




% cause of 
death
%
Total 1548 100.0 545 100.0
Squamous-cell carcinomas 967 62.5 333 61.1
8052 Papillary squamous-cell carcinoma 1 0.1 0 0.0
8070 Squamous-cell carcinoma, NOS 746 48.2 328 60.2
8072 Squamous large-cell, nonkeratinising carcinoma 1 0.1 0 0.0
8076 Squamous-cell microinvasive carcinoma 217 14.0 4 0.7
8083 Basaloid squamous-cell carcinoma 1 0.1 1 0.2
8084 Clear-cell squamous carcinoma 1 0.1 0 0.0
Adenocarcinomas 453 29.3 151 27.7
8140 Adenocarcinoma, NOS 402 26.0 139 25.5
8260 Papillary adenocarcinoma, NOS 3 0.2 1 0.2
8310 Clear-cell adenocarcinoma, NOS 2 0.1 0 0.0
8380 Endometrioid adenocarcinoma, NOS 35 2.3 7 1.3
8384 Adenocarcinoma, endocervical type 4 0.3 0 0.0
8441 Serous cystadenocarcinoma, NOS 2 0.1 1 0.2
8460 Papillary serous cystadenocarcinoma 1 0.1 1 0.2
8480 Mucinous adenocarcinoma 2 0.1 2 0.4
9110 Mesonephroma 2 0.1 0 0.0
Other specified epithelial tumours 37 2.4 11 2.0
8013 Large-cell neuroendocrine carcinoma 1 0.1 0 0.0
8015 Glassy-cell carcinoma 2 0.1 1 0.2
8041 Small-cell carcinoma 6 0.4 4 0.7
8098 Adenoid basal carcinoma 3 0.2 0 0.0
8200 Adenoid cystic carcinoma 3 0.2 1 0.2
8246 Neuroendocrine carcinoma, NOS 6 0.4 0 0.0
8560 Adenosquamous carcinoma 16 1.0 5 0.9
Epithelial tumour, NOS 21 1.4 16 2.9
8010 Unclassified carcinoma 21 1.4 16 2.9
Other specified tumours 23 1.5 4 0.7
8800 Sarcoma, NOS 2 0.1 1 0.2
8890 Leiomyosarcoma, NOS 5 0.3 0 0.0
8910 Embryonal rhabdomyosarcoma, NOS 2 0.1 0 0.0
8933 Adenosarcoma 1 0.1 0 0.0
8935 Stromal sarcoma, NOS 3 0.2 1 0.2
8950 Mullerian mixed tumour 1 0.1 0 0.0
8980 Carcinosarcoma, NOS 6 0.4 1 0.2
8990 Mesenchymoma 2 0.1 1 0.2
9100 Choriosarcoma, NOS 1 0.1 0 0.0
Other neoplasm, NOS 47 3.0 28 5.1
8000 Unclassified malignancy 47 3.0 28 5.1
Table 6: Morphology of malignant tumours of the uterine cervix diagnosed or causing death in Finland in 
2000–2009 (source of case material in papers IV and V)
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8.2.3 the hospital disCharge register
Since 1996, ICD-10 diagnosis codes have been used to register inpatient episodes 
and day-surgical procedures in the HDR. From 1998 onward, all outpatient visits 
in the public sector have been registered. Data include visit diagnosis, treatments 
given, and date of visit or discharge. The diagnoses found in this register usually 
cannot be used as incidence data without further information generated, for example 
through linkage to other health-care registers.
8.3 linkage of data sourCes
8.3.1 linking registers of CerviCal lesions (i)
Accurate linkage of register data is possible and relatively simple because of the 
personal identifier given to all residents of Finland. For comparison of the histo-
logical diagnoses found in the various data sources, we chose a time period when 
also the HDR and the cancer register could be expected to have good coverage 
of precancerous lesions – i.e., 1998 onwards. We started with the population of 
women screened in 1998–2007 who had received a referral for colposcopy because 
of a positive screening test and therefore should have a histologically confirmed 
diagnosis in the screening register. In the years examined, there were 16,353 refer-
rals, involving 15,912 women. The confirmed histological diagnoses resulting from 
these referrals included 4,309 cases of CIN1–2, 2,152 cases of CIN3/AIS, and 185 
cases of ICC. The referrals were linked to the HDR, which yielded 54,263 cervical, 
vulvar, vaginal, and uteral health-care contact episodes, involving 12,832 women. 
For 2,644 of these women, an invasive or pre-invasive diagnosis was found in the 
FCR. We were interested especially in the completeness and accuracy of screening 
registration and had to define the diagnoses found in the other two registers by 
the mode of detection in relation to screening. We used the criterion of diagnosis 
within 12 months of a positive screening test (i.e., a screening test with a referral 
for histological confirmation) for defining a diagnosis as screendetected, and hence 
eligible for inclusion in the screening records. Whenever multiple diagnoses were 
found within this time window in a register, the highest-grade cervical neoplastic 
lesion or cancer was chosen.
The diagnosis in the cancer register was regarded as the most accurate available, 
because of multiple notifications and the verification procedures in use. However, 
in the 10 cases wherein an invasive cancer was suggested by either of the other two 
registers and no record for the woman existed in the cancer register, a thorough 
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review of the patient history records was done. The review resulted in updating 
of the cancer register with two additional ICC diagnoses and a change of primary 
site from an undetermined female genital cancer to specifically the cervix in one 
instance. The updated cancer register records on ICC were used as reference in the 
subsequent comparisons of registers.
8.3.2 potential false-negative sCreening tests (ii and iii)
For auditing of screening-test performance, seven screening laboratories active 
during the 1990s were recruited and the data in the screening register correspond-
ing to the active time for each laboratory were linked with the cancer register 
files for CIN3/AIS and ICC in 1990–1999. The screening records included in the 
linkage amounted to 953,610 screen samples. Audit cases were defined as CIN3+ 
diagnoses preceded by a Pap I or Pap II screening test that did not result in a 
referral. These tests were regarded as potentially false negative and were included 
in the review phase.
8.3.3 CanCer audit of sCreening histories with Controls (iv and v)
For the evaluation of effectiveness, all ICC cases diagnosed in 2000–2009 and all 
deaths due to cervical cancer in 2000–2009 were age-matched by birth month 
and year to six controls from the population register. Women had to be alive and 
not diagnosed with cervical cancer at the time of diagnosis of their matched case. 
Two incident-case women had data restriction in place and were excluded from 
the screening history and case–control analysis for a final incidence-case count 
of 1,546. The cases and the controls were then linked to the screening register 
data from 1990–2009. There were 39 cases of death with index invitation by age 
before 1990. These cases and their controls were excluded from the screening his-
tory analysis because we did not have data on the screening exposure. The final 
sum of cases of cervical cancer death in the screening history and case–control 
analysis was 506.
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8.4 mode of deteCtion and sCreening history
8.4.1 mode of deteCtion (iv and v)
The mode of detection with respect to screening is a variable that has relevance 
only for cases of cervical cancer, not controls. This type of classification has been 
recommended by the ENCR (ENCR 2001) for routine use by cancer registers for 
cancers targeted by screening, and an updated classification was used for the first 
time in the Finnish Cancer Registry for cervix and breast cancers in 2011 (Finn-
ish Cancer Registry 2011). Cases can occur in the non-invited population, among 
nonparticipants, or among those participating in screening. Participants’ cases are 
further separated into screen-detected and interval cases. Screen-detection was 
defined as the diagnosis of cancer within 12 months of a positive screening test 
with referral for colposcopy and biopsies. This definition is recommended by the 
European guidelines (Arbyn et al. 2008a) and is especially suitable for application 
in the Finnish screening programme because of the near-perfect compliance with 
the referral colposcopy (Ronco et al. 2009).
8.4.2 preventive-sCreening status (iv and v)
The item for preventive-screening status represents screening exposure and can 
therefore be addressed for cases and controls alike. For studying the effectiveness 
of screening tests, we used the outcome of the age-group invitational screening 
event immediately preceding the date of diagnosis of the case, or the correspond-
ing date for the matched controls, as the determinant of exposure. Because of 
the default five-year interval in the Finnish screening programme, this index 
screening event was defined as the last age-group programme test within the 66 
months preceding diagnosis. This period is the sum of the five-year screening 
interval and a six-month allowance for test date variation within the invitation 
year. Screening events leading to the detection of cancer were disregarded, as 
they do not contribute to the preventive impact of screening. Instead, the pre-
vious invitational screening event was used to determine the index-screening 
status of screen-detected cases and their matched controls, thus maintaining 
equal opportunity of exposure for cases and controls. The outcome of the last 
invitational screening event was indexed as negative when there was no further 
recommendations made and the default screening interval was applied, bor-
derline when a recommendation for re-screening within a shorter interval was 
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made, and referral when there was a recommendation for colposcopy directly 
as a result of the age-group invitational smear.
8.5 review of arChived smears (ii and iii)
Sensitivity failure of screening can be expressed in terms of false-negative tests or 
episodes. To this end, we used the rereading of archived smears that were classi-
fied as negative in the sense that no referral for further confirmation was made but 
that nevertheless preceded a diagnosis of CIN3+. There were 474 such case smears 
in the cytology audit (II and III). These smears, and two sequential smears for 
controls, were requested from the archives of participating laboratories, and 395 
(83%) were retrieved, along with 787 controls. Laboratories then reanalysed their 
own smears, cases and controls, while blinded to the original reading and the case 
history. All smears also underwent blinded analysis by a reference laboratory at 
the Department of Gynaecology and Obstetrics of the Helsinki University Central 
Hospital. Whenever these two readings differed significantly from each other (207 
case smears and 159 control smears), the smear was additionally analysed by an 
expert panel who then provided the best attainable, or gold standard, cytology. At the 
end of this process, each smear had four cytology results: the original result (either 
Pap I or Pap II), the laboratory reanalysis result, the reference laboratory’s result, 
and the gold standard cytology. Any smears upgraded to positive cytology by the 
gold standard were considered clearly positive false negatives, while comparisons of 
the different readings were used for estimation of test validity and reproducibility.
8.6 statistiCal methods
8.6.1 validation of the register diagnosis (i)
Completeness of records was described by two measures. These were coverage, re-
ferring to the presence of any diagnosis wherein a neoplastic diagnosis was present 
according to the reference standard, and sensitivity, referring to the presence of a 
diagnosis at least as severe as that suggested by the reference standard. The cancer 
register was used as a reference standard for invasive disease, and for CIN3+, CIN2+, 
and CIN1+, the reference standard was the population of cases above each threshold 
of severity according to at least one of the three registers under comparison.
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The PPV and the kappa coefficient were used to describe accuracy of register 
diagnosis. The PPV was only for ICC diagnoses only and corresponds to the propor-
tion confirmed by the FCR. Linearly weighted kappa coefficients were calculated for 
pair-wise inter-rater agreement of specific register diagnoses (Gwet 2002).
8.6.2 Cytology audit and laboratory performanCe (ii and iii)
False negativity was calculated with two cut-off points for both the original reading 
and the reference cytology. The smears included in the audit were originally Pap 
I or Pap II. The Pap II class includes borderline changes that can be indicative of 
dysplasia but also a large proportion of reactive, or benign, findings. We did not 
have the means to distinguish these groups, so the main results were presented 
with both Pap I and Pap II included as originally negative smears. Accordingly, the 
main cut-off for the gold-standard cytology used as reference was LSIL+, which 
generally requires a referral for colposcopy. As the reporting of cytology moved from 
a modified Papanicolaou classification to Bethesda 2001 terminology in 2006, the 
review was recorded in terms of Bethesda.
For test sensitivity, we used the results of the review of case and control slides 
in the original laboratory in comparison to the gold-standard cytology. We calcu-
lated proportions of smears correctly diagnosed at three thresholds or higher. The 
lowest threshold was ASC-US+, which is the minimum requirement for abnormal 
smears, as it will at least trigger the intensified screening protocol. The intermediate 
threshold was LSIL+, which usually triggers a referral for colposcopy, and the high-
est threshold used was HSIL+, representing a high risk of dysplasia that requires 
treatment and more urgent referral. The inclusion of controls in the review enabled 
us also to calculate specificity, which was equivalently reported as the proportion 
of smears correctly reported below the above-mentioned thresholds. Confidence 
limits for sensitivity and specificity were estimated at 95% confidence levels assum-
ing a binomial distribution.
Inter-observer reproducibility of cytology was analysed by cross-tabulation of 
the original laboratory rereading results with the reference-laboratory results. Un-
weighted and linearly weighted kappa statistics were estimated both for specific 
cytological results and for results grouped into three categories by resulting rec-
ommendation (normal screening interval, intensified screening, and referral for 
colposcopy).
Performance indicators for each participating laboratory were tested for hetero-
geneity in logistic regression models with age and year as explanatory variables. For 
heterogeneity testing, we restricted the material to the years when all participating 
laboratories were active, in order to have equal opportunity for cases to arise in 
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follow-up. The performance indicators tested included the intensified-screening rec-
ommendation rate; the referral rate; detection rates of CIN1+, CIN2+, and CIN3+; 
and PPVs for CIN1+, CIN2+, and CIN3+. The audit CIN3+ case rate compared to 
total screening tests and the proportion of audit CIN3+ cases to all CIN3+ cases 
were used as outcome indicators. The heterogeneity across laboratories for the 
former was tested in a logistic regression model, and the heterogeneity of the latter 
was tested in a log-binomial regression model of age and year.
8.6.3 sCreening effeCtiveness (iv and v)
Screening effectiveness was estimated in a case–control design with screening at-
tendance in the index screening event as exposure. Conditional logistic regression 
was used to estimate the odds ratios for the association of attendance and either 
cervical cancer (IV) or cervical cancer death (V), with a date of diagnosis in the screen-
ing interval up to and including any screen-detected diagnoses from the following 
screening event. In order to account for selection bias – that is, the difference in 
baseline risk between those choosing to attend and those choosing not to attend – a 
self-selection factor (Sf) was utilised. The self-selection factor was estimated as the 
risk ratio (approximated by the odds ratio) of those choosing not to attend screening 
after invitation and those not invited within the matched case–control material. 
This factor was based on all cervical cancers (including microinvasive carcinomas) 
for correction of the ORs for the effects on incidence and FIGO stageIB+ cancers 
for correction of the ORs for the estimated effects on mortality. Multiplying the 
crude OR by Sf would yield an OR approximating the relative risk of disease in the 
participants as compared to those not invited, which is not an estimate of screening 
effect. The risk of all women not invited is higher than the risk of those who would 
participate if invited, so the correction is too small. Information on participation is 
needed also; hence, the corrected ORs for screening effect were generated through 
application of Formula 5:
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restricted the material to the years when all participating laboratories were active, in order to have 
equal opportunity for cases to arise in follow-up. The performance indicators tested included the 
intensified-screening recommendation rate; the referral rate; detection rates of CIN1+, CIN2+, and 
CIN3+; and PPVs for CIN1+, CIN2+, and CIN3+. The audit CIN3+ case rate compared to total 
screening tests and the proportion of audit CIN3+ cases to all CIN3+ cases were used as outcome 
indicators. The heterogeneity across laboratories for the former was tested in a logistic regression 
model, and the heterogeneity of the latter was tested in a log-binomial regression model of age and 
year.
8.6.3  Screening effectiveness (IV and V) 
Screening effectiveness was estimated in a ca e–control design with screening attendance in the
index screening event as exposure. Conditional logistic regression was used to estimate the odds 
ratios for the association of attendance and either cervical cancer (IV) or cervical cancer death (V), 
with a date of diagnosis in the screening interval up to and including any screen-detected diagnoses 
from the followi g screening ev nt. In order to account for selecti  bias – that is, the difference in 
baseline risk between those choosing to attend and those choosing not to attend – a self-selection 
factor (Sf) was utilised. The self-selectio  f ctor was estimated as th  risk ratio (approximated by 
the odds ratio) of those choosing not to attend screening after invitation and those not invited within 
the matched case–control material. This factor was based on all cervical cancers (including 
microinvasive carcinomas) for correction of the ORs for the effects on incidence and FIGO 
stage-IB+ cancers for correction of the ORs for the estimated effects on mortality. Multiplying the 
crude OR by Sf would yield an OR approximating the relative risk of disease in the participants as 
compared to those not invited, which is not an estimate of screening effect. The risk of all women 
not invited is higher than the risk of those who would participate if invited, so the correction is too 
small. Information on participation is needed also; hence, the corrected ORs for screening effect 
were generated through application of Formula 5:
𝑂𝑂𝑂𝑂𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
𝑝𝑝 × 𝑂𝑂𝑂𝑂𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 × 𝑆𝑆𝑆𝑆
1 − (1 − 𝑝𝑝) × 𝑆𝑆𝑆𝑆
from the methodology paper by Duffy et al. (2002). This formula is applicable to self-selection 
corrections in screening evaluations and has previously been used in case–control studies of the 
from the methodology paper by Duffy et al. (2002). This formula is applicable to 
self-selection corrections in screening evaluations and has previously been used 
in case–control studies of the effectiveness of breast cancer screening (Otto et al. 
2012). The participation rate (p, 71%) of those invited in the screening programme 
in 1990–2009 was used in the correction.
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The above formula estimates the effect as the risk in those participating com-
pared to those who would participate if invited. Because of heterogeneity in the 
participation rates by age at invitation, we also produced age-specific self-selection 
factors by applying the following formula of our own derivation:
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effectiveness of breast cancer screening (Otto et al. 2012). The participation rate (p, 71%) of those 
invited in the screening programme in 1990–2009 was used in the correction.
The above formula estimates the effect as the risk in those participating compared to those who 
would participate if invited. Because of heterogeneity in the participation rates by age at invitation, 
we also produced age-specific self-selection factors by applying the following formula of our own 
derivation:
𝑆𝑆𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎 = 𝑆𝑆𝑆𝑆 �
1 − 𝑝𝑝
1 − 𝑝𝑝𝑎𝑎𝑎𝑎𝑎𝑎




Here, p is the overall participation rate, 0.71; page is the age-specific participation rate; Sf is the 
overall odds ratio of those not participating as compared to those not invited; Tf is the odds ratio of 
those who would participate if invited when compared to those not invited, which cannot be 
observed directly but can be derived from the formula (1 − 𝑝𝑝) × 𝑆𝑆𝑆𝑆 + 𝑝𝑝 × 𝑇𝑇𝑆𝑆 = 1; and, finally, 
Sfage is the age-specific self-selection factor. The calculation of Sfage rests on the assumption that the 
higher risk observed in non-participants is due to a small group of high-risk women who do not 
participate at any age. The high risk of these women is assumed to be due to lifestyle risk factors 
such as a large number of sexual partners, smoking, low use of health care services, and low 
socio-economic status, all of which may also correlate negatively with screening attendance. 
Whenever the participation rate is lower, more women at low risk also fail to participate, thereby 
diluting the high risk of the non-participants and causing the self-selection factor to decline toward 
1. When the participation rate is higher, the higher risk of non-participants is concentrated and the 
self-selection factor will become larger.
Here, p is the overall participation rate, 0.71; page is the age-specific participation 
rate; Sf is th overall odds r o of those not participating as compared to tho e not 
invited; Tf is the odds ratio of those who would participate if invited when com-
pared to those not invited, which cannot be observed directly but can be derived 
from the formula (1 - p) x Sf + p x T  = 1 ; and, finally, Sfage is the age-specific self-
selection factor. The calculation of Sfage rests on the assumption that the higher risk 
observed in non-participants is due to a small group of high-risk women who do 
not participate at any age. The high risk of these w men is assumed to be due to 
lifestyle risk factors such as a large number of sexual partners, smoking, low use of 
health care services, and low socioeconomic status, all of which may also correlate 
negativ ly with screening attendance. Whenever the participation rate is lower, 
more women at low risk also fail to participate, thereby diluting the high risk of the 
non-participants and causing the self-selection factor to decline toward 1. When 
the participation rate is higher, the higher risk of non-participants is c ncentrated 
and the self-selection factor will become larger.
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9 results
9.1 register quality (i)
In 1998 to 2007 there were 1.9 million screening tests, 16,353 referrals for histo-
logical confirmation, and 6,646 precancerous lesions or cancers associated with 
the cervix registered in the screening programme. The coverage of screen-detected 
cervical lesion in the screening register was very high at all levels of lesion severity 
(see Table 7). The sensitivity of CIN diagnoses was also high in comparison with the 
other registers. However, the sensitivity of the ICC diagnosis was 69%, the lowest 
value of the three registers under comparison. The PPV of an ICC diagnosis in the 
screening register was found to be 77%. However, all cases were confirmed by FCR 
records and notifications as at least CIN2 neoplasias. The kappa value for inter-rater 
agreement between the MSR and the FCR was evaluated at 0.79.
ICC CIN3+ CIN2+ CIN1+
Reference standard (n ) 207 2,874 5,176 7,183
MSR
Sensitivity (%) 68.6 81.3 89.2 92.5
Coverage (%) 100.0 99.4 99.3 99.4
HDR
Sensitivity (%) 80.7 74.9 78.3 75.8
Coverage (%) 100.0 92.7 92.5 90.5
FCR
Sensitivity (%) 98.6 79.5 NA NA
Coverage (%) 99.0 79.5 NA NA
Table 7: Sensitivity and coverage of register diagnosis by threshold 
of lesion severity
9.2 false negatives (ii and iii)
The study material for studies II and III, which included smears taken by seven 
cytology laboratories during 1990–1999, covered 1,312,139 invitations and 953,610 
smears. There were 9,062 (1.0%) referrals for colposcopy based on these smears 
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and 1,152 screen-detected CIN3+ cases. Audit cases (i.e., cases of CIN3+ pre-
ceded by Pap I or Pap II smears without referral for colposcopy) numbered 474. 
Of these, 395 (83%) were retrieved for review. The overall falsenegative rate was 
38% among cases and 3.2% among controls (see Table 8). There were no significant 
differences in false-negative rates between invasive audit cases and CIN3/AIS audit 
cases. As expected, the falsenegative rates were higher among those with smears 
originally classified as Pap II (63%) than those originally classified as Pap I (24%). 
Those Pap I smears that were classified as at least borderline abnormal (ASC-US+) 
at review amounted to 53% of all audit cases and 14% of all controls.
Final review result
ASCUS+ LSIL+ HSIL+
n  (%) n  (%) n  (%)
Smears without referral in study 944,548
Identified audit smears 474
Audit smears in study 395 221 (56) 151 (38) 94 (24)
Cx cancer 58 31 (53) 22 (38) 15  (26)
Pap I 42 15 (36) 11 (26) 8 (19)
Pap II 16 16 (100) 11 (69) 7 (44)
CIN3/AIS 337 190 (56) 129 (38) 79 (23)
Pap I 210 87 (41) 49 (23) 29 (14)
Pap II 127 103 (81) 80 (63) 50 (39)
Controls in study 787 109 (14) 25 (3.2) 9 (1.1)
Pap I 743 83 (11) 14 (1.9) 5 (0.7)
Pap II 44 26 (59) 11 (25) 4 (9.1)
Table 8: Cumulative frequencies of final cytology review result by smear status and 
original cytology
9.3 sCreening-test validity (ii)
Sensitivity and specificity of cytology in the screening laboratories in the review 
phase was evaluated with respect to the final review results (see Table 9). The sen-
sitivity of the screening laboratory’s review at the threshold of LSIL+ (equivalent to 
abnormalities usually requiring colposcopy) was 56%, and the specificity was 99%. 
Some 20% of these smears were deemed normal by the screening laboratories. At 





ASC-US+ 64.2 79.6 85.4
LSIL+ 32.7 55.7 66.2
HSIL+ 18.8 31.8 47.6
Specificity
ASC-US+ 97.4 90.7 86.5
LSIL+ 99.9 98.9 96.2
HSIL+ 100.0 99.4 98.8
Table 9: Sensitivity and specificity of the review 
performed by the screening laboratories with 
respect to final cytology results
The inter-observer reproducibility of cytology was evaluated via comparison of 
the review results of the original screening laboratories with the review results of the 
reference laboratory (see Table 10). For the detail-level Bethesda categories, there 
was 69% agreement between the two reviewing laboratories. The unweighted kappa 
statistic indicated fair agreement, at 0.26. The results were also grouped according 
to the recommendation given. The three categories used were normal, intensified 
screening protocol for ASC-US and AGC-NOS, and LSIL or indication of more se-
vere abnormality – considered a basis for referral. For these three categories, there 
was 84% agreement between the laboratories and a kappa value of 0.59, suggesting 
that the agreement was moderate. When these three recommendation categories 
were further analysed with a linear weighting for level of disagreement, the kappa 
statistic indicated substantial agreement (0.66).Ensin Picture (windows metafile) formaatti joka siis sama kuin edellisissä materiaaleissa: 
 
Table 10: Inter-observer reproducibility of cytology
Reference laboratory
Screening laboratory Normal ASC-US AGC-NOS LSIL ASC-H HSIL AGC-FN Ca Total
Normal 751 102 41 13 14 20 7 0 948
ASC-US 46 23 7 7 5 8 5 0 101
AGC-NOS 11 3 3 1 1 2 3 0 24
LSIL 4 2 0 8 0 7 3 0 24
ASC-H 10 3 2 2 3 2 1 0 23
HSIL 6 8 2 1 7 21 3 1 49
AGC-FN 0 1 3 0 1 3 2 0 10
Ca 0 0 0 1 0 1 0 1 3
Total 828 142 58 33 31 64 24 2 1,182
Cohen's unweighted κ  statistic is 0.26. For the three categories of normal, intensified screening protocol, and referral, the 
unweighted κ  = 0.59 and linearly weighted κ  = 0.66.  
 




Table 5: Invitation coverage of the cervical screening programme in Finland in 1990–2009 (%)
Age 1990–1994 1995–1999 2000–2004 2005 2006 2007 2008 2009
25 40 32 36 35 28 30 29 15
30 70 74 89 93 92 94 98 98
35 92 92 98 98 98 99 99 100
40 98 99 99 99 99 100 100 100
45 98 95 97 99 99 100 100 100
50 98 99 100 100 99 100 100 100
55 79 91 97 98 96 98 100 100
60 59 76 88 95 94 97 99 99
65 12 15 16 16 15 16 16 3




9.4 performanCe indiCators (iii)
Performance or process indicators for the seven laboratories participating in the 
cytology audit are presented in Table 11. All cross-sectional performance indicators 
were heterogeneous across laboratories. The referral rate varied from 0.3% to 1.2% 
(fourfold), with an average of 1.0%. The rate of recommendations for intensified 
screening varied from 2.8% to 10.2%, and the average was 5.4%. Consequently, 
the PPVs, especially for CIN3+ histology, showed considerable, eightfold varia-
tion, from 5% to 41%, with an average of 13%. False-negative proportions for the 
audited CIN3+ case smears at a threshold of LSIL+ ranged from 29% to 62% and 
had an average of 38%. Review sensitivity and specificity too were highly variable. 
However, there was less variation in the longitudinal outcome indicators. The audit 
case rate out of all smears taken by the laboratory varied by a factor of two, from 
0.023 to 0.048, and the proportion of all CIN3+ cases that were screen-detected in 
the programme ranged from 69% to 85%. The two outcome indicators did not show 
statistically significant heterogeneity when formally tested by likelihood ratio tests. 
Table 11: Performance parameters and outcome indicators by laboratory (%)
Screening laboratory, with number of smears
A B C D E F G All
265,536 177,948 162,478 109,354 105,241 78,481 54,572 953,610
Attendance 68 73 76 69 81 79 74 73
Referrals 1.2 1.0 1.2 1.1 0.4 0.6 0.3 1.0
Intensified screening 6.9 3.2 3.2 8.3 2.8 10.2 4.4 5.4
CIN1/CIN3+ (ratio) 1.15 1.00 2.39 0.65 0.41 0.81 0.17 0.98
PPV (CIN3+) 13 12 5 16 31 18 41 13
PPV (CIN2+) 24 20 13 38 46 33 57 25
PPV (CIN1+) 38 32 24 48 58 48 63 37
False-negative rate* 30 29 44 62 32 50 39 38
Review sensitivity (LSIL+) 50.9 63.6 45.2 78.4 23.8 78.6 55.6 55.7
Review specificity (LSIL+) 99.5 96.7 100.0 94.6 100.0 100.0 97.8 98.9
Audit case rate† 0.030 0.028 0.025 0.048 0.044 0.027 0.023 0.034
Proportion detected by screen 84 80 69 79 85 81 85 80
out of all CIN3+ cases‡
* Proportion of originally Pap I or Pap II smears in audit with final review cytology of LSIL+
† Audit CIN3+ cases diagnosed after Pap I or Pap II screen in 1996-1999 divided by all smears taken in the period
‡ In period 1996-1999.
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9.5 age at diagnosis and mode of deteCtion  
 (iv and v)
Microinvasive carcinomas (FIGO stage IA) were most frequently diagnosed just 
after the age of 30 (see Figure 2). The frankly invasive cancer (FIGO stage IB+) 
frequency had two peaks, the first some years after age 35 and the other at around 
age 75. Cervical cancers that caused death were diagnosed predominantly toward 
older ages, and the frequency peaked at around 80. There were no deaths associated 
with cervical cancers diagnosed before age 25, and only nine cases with cancers 
were diagnosed before the age of 30.
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9.5  Age at diagnosis and mode of detection (IV and V) 
 
Microinvasive carcinomas (FIGO stage IA) were most frequently diagnosed just after the age of 30 
(see Figure 2). The frankly invasive cancer (FIGO stage IB+) frequency had two peaks, the first 
some years after age 35 and the other at around age 75. Cervical cancers that caused death were 
diagnosed predominantly toward older ages, and the frequency peaked at around 80. There were no 
deaths associated with cervical cancers diagnosed before age 25, and only nine cases with cancers 
were diagnosed before the age of 30. 
 
Figure 2. Age at diagnosis for all incident FIGO stage-IA and stage-IB+ cervical cancers in Finland in 2000–2009 
(n = 1,548) and age at diagnosis for all cases of death attributed to cervical cancer in Finland in 2000–2009 (n = 
545). Frequencies are smoothed by kernel density estimation for better visualisation. 
 
 
Nearly one third of all cancers and more than half of the cancers leading to death were diagnosed 
more than five years after the last programme invitation (see Figure 3). The second largest group 
was that of the non-attenders; 28% of cancers and 24% of deaths occurred in this group. The 
screen-detected cancers accounted for 11% of cancers but only 3% of deaths. Interval cancers were 

















figure 2. Age at diagnosis for all incident FIGO stage-IA and stage-IB+ cervical cancers in Finland 
in 2000–2009 (n = 1,548) and ag  at diagnosis for ll cases of death ttributed to cervical cancer 
in Finland in 2000–2009 (n = 545). Frequencies are smoothed by kernel density estimation for 
better visualisation.
Nearly one third of all cancers and more th n half of the cancers l ading to death 
were diagnosed more than five years after the last programme invitation (see Figure 
3). The second largest group was that of the non-attenders; 28% of cancers and 
24% of deaths occurred in this group. The screendetected cancers accounted for 
11% of cancers but only 3% of deaths. Interval cancers were also less common as a 
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cause of death (13% of all deaths) than among all cancer diagnoses (19%). A small 
proportion (4.4%) of cancers was diagnosed before first programme invitation, and 
only 1.6% of the deaths were due to these cancers.
 63
also less common as a cause of death (13% of all deaths) than among all cancer diagnoses (19%). A 
small prop  (4.4%) of cancers was diagnosed before first prog amme invitation, and only 1.6% 
of the deaths were due to these cancers. 
 
 
Figure 3. Cervical cancers and cervical cancer deaths (Finland, 2000–2009), that were included in the study, by 




9.6  Evaluation of screening effect 
 
The proportions of those without invitation in the index round were similar between cases and 
controls for both the incident cervical cancers and the deaths (Table 12; papers IV and V). This was 
expected, as lacking an invitation was mainly due to diagnosis outside the programme target age 
range so indirectly matched for. However, clear differences were observed in the proportions of 
non-attenders and attenders. Out of the incident cases, 32% were non-attenders in the index round, 
as compared to 20% of their controls. The difference was even larger among cancer deaths, for 
which invited non-attenders were more than twice as common as among the controls. Four cases of 
cancer were diagnosed after a negative HPV test, whereas there were no deaths due to cancers in 





















Cervical cancer deaths, n=506
figure 3. Cervical cancers and cervical cancer deaths (Finland, 2000–2009), that were included in 
the study, by mode of detection in relation to screening.
9.6 evaluation of sCreening effeCt
The proportions of those without invitation in the index round were similar between 
cases and controls for both the incident cervical cancers and the deaths (Table 
12; papers IV and V). This was expected, as lacking an invitation was mainly due 
to diagnosis outs e h  progr mme target age range so indirectly m tched for.
However, clear differences were observed in the proportions of non-attenders and 
attenders. Out of the incident cases, 32% were non-attenders in the index round, 
as compared to 20% of their controls. The difference was even larger among can-
cer deaths, for which invited non-attenders were more than twice as common as 
among the controls. Four cases of cancer were diagnosed after a negative HPV test, 
whereas there were no deaths due to cancers in this category. No deaths were due 
to cancers diagnosed ft r a colposcopy in th  ind x round.
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n % n % n % n %
Total 1,546 100.0 9,276 100.0 506 100.0 3,036 100.0
No invitation 686 44.4 3,994 43.1 308 60.9 1,818 59.9
Before first invitation 91 5.9 503 5.4 8 1.6 36 1.2
Over screening age* 487 31.5 2,920 31.5 270 53.4 1,609 53.0
Other reason 108 7.0 571 6.2 30 5.9 173 5.7
Non-attender 494 32.0 1,813 19.5 127 25.1 342 11.3
Never attended† 414 26.8 1,595 17.2 98 19.4 201 6.6
Lapsed attender 80 5.2 218 2.4 29 5.7 141 4.6
Screened 366 23.7 3,469 37.4 71 14.0 876 28.9
Negative cytology 254 16.4 3,190 34.4 64 12.6 817 26.9
Borderline cytology 94 6.1 164 1.8 6 1.2 37 1.2
Negative HPV test 4 0.3 96 1.0 0 0.0 15 0.5
Referral non-compliance 1 0.1 1 0.0 1 0.2 1 0.0
Negative histology 6 0.4 9 0.1 0 0.0 2 0.1
Positive histology 7 0.5 9 0.1 0 0.0 4 0.1
* Diagnosis five years or more after last programme invitation
†  During period 1990-2009.
Table 12: Screening status of index round at time of cancer diagnosis for cases and on corresponding date for 
matched controls
Incident cervical cancers Cervical cancer deaths
Cases ControlsCases Controls
9.6.1 sCreening effeCtiveness (iv and v)
Self-selection-corrected odds ratios of the association between cervical cancer and 
participation in programme screening indicate that there was little or no effect of 
screening at ages 25–29 (see Figure 4). Programme participation between ages 
30 and 39 was associated with a 21–27% reduction in cancer risk, but this effect 
estimate was not significant. From the age of 40, the risk reduction exceeded 50% 
for all five-year age bands, but the point estimate for the last five-year age group, 
65–69, was non-significant.
Age-specific odds ratios of programme participation by morphology and for cer-
vical cancer death were estimated in 15-year age groups for more robust estimates 
(see Table 13). The ORs for SCC were similar to those for all cancers. However, 
there was a suggestion of stronger effect in the older age groups, especially with 
death as an outcome. The effect on the risk of adenocarcinoma was smaller and 
the estimates non-significant for death due to adenocarcinoma in the various age 
groups and overall. Point estimates suggested a higher impact of screening on the 
risk of death than on the risk of cervical cancer, except for adenocarcinoma. The 
overall reduction of cervical cancer risk produced by one age-group-programme 
test was estimated at 47% (95% CI: 38–54%) whereas overall reduction in risk of 




Figure 4. Odds ratios of the association of screening programme participation and cervical cancer in the 
following five-year period. Estimates are corrected for self-selection bias, with self-selection factor 1.29 and a 
participation rate of 71%. Confidence intervals (95%) are shaded grey. 
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age groups, especially with death as an outcome. The effect on the risk of adenocarcinoma was 
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figure 4. Odds ratios of the association of screening programme participation and cervical cancer 
in the following five-year period. Estimates are corrected for self-selection bias, with self-selection 
factor 1.29 and a participation rate of 71%. Confidence intervals (95%) are shad d grey.
Cancer morphology Age at invitation Crude OR Corrected OR* Crude OR Corrected OR*
All cervical cancers All (25–69) 0.37 0.53 (0.46–0.62) 0.19 0.34 (0.14–0.49)
25–39 0.56 0.81 (0.63–1.05) 0.44 0.70 (0.33–1.48)
40–54 0.30 0.44 (0.35–0.56) 0.18 0.33 (0.20–0.56)
55–69 0.25 0.37 (0.27–0.52) 0.15 0.29 (0.16–0.54)
Squamous carcinoma All (25–69) 0.34 0.50 (0.41–0.61) 0.12 0.22 (0.13–0.36)
25–39 0.62 0.91 (0.67–1.24) 0.61 0.97 (0.39–2.41)
40–54 0.27 0.40 (0.29–0.54) 0.06 0.11 (0.05–0.28)
55–69 0.16 0.23 (0.14–0.37) 0.09 0.17 (0.07–0.44)
Adenocarcinoma All (25–69) 0.47 0.69 (0.53–0.91) 0.42 0.75 (0.43–1.31)
25–39 0.41 0.59 (0.36–0.98) 0.32 0.50 (0.09–2.76)
40–54 0.42 0.61 (0.41–0.91) 0.65 1.21 (0.53–2.75)
55–69 0.60 0.88 (0.50–1.54) 0.28 0.55 (0.23–1.35)
Table 13: Odds ratios for the association between cervical cancer or cervical cancer death and screening 
participation by cancer morphology
Cervical cancer Cervical cancer death
* Overall ORs were corrected via participation rate (p) 0.71, self-selection factor (Sf) 1.29 for incidence and 
1.45 for death. Age-group-specific self-selection factors were used for ORs associated with death: Sf  1.30 
and p  0.62 for the age group 25–39, Sf  1.51 and p  0.74 for the age group 40–54, and Sf  1.63 and p  0.77 
for the age group 55–69. The overall values were used for all ORs associated with incidence. 95% CIs of 
estimates are indicated. 
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Small adjustments in the point estimates were observed when age-specific cor-
rection was used also for the ORs of the association between screening participation 
and cancer incidence (see Table 14, presenting results not previously published). 
OR with Participation Self-selection
Age at invitation overall correction rate factor
Overall 0.53 (0.46–0.62) 0.71 1.29 NA
25–39 0.81 (0.63–1.05) 0.62 1.19 0.75 (0.58–0.98)
25–29 0.95 (0.36–2.49) 0.56 1.15 0.85 (0.37–1.93)
30–34 0.79 (0.53–1.16) 0.60 1.18 0.72 (0.49–1.07)
35–39 0.73 (0.50–1.06) 0.66 1.23 0.70 (0.48–1.01)
40–54 0.44 (0.35–0.56) 0.74 1.33 0.46 (0.36–0.58)
40–44 0.38 (0.26–0.58) 0.72 1.30 0.39 (0.26–0.58)
45–49 0.41 (0.27–0.62) 0.73 1.33 0.43 (0.28–0.64)
50–54 0.44 (0.29–0.68) 0.76 1.38 0.47 (0.31–0.73)
55–69 0.37 (0.27–0.52) 0.77 1.40 0.41 (0.29–0.57)
55–59 0.34 (0.22–0.52) 0.77 1.40 0.37 (0.24–0.57)
60–64 0.49 (0.28–0.84) 0.78 1.42 0.54 (0.31–0.93)
65–69 0.49 (0.10–2.41) 0.75 1.35 0.53 (0.17–2.62)
OR with age-
specific correction
Table 14: ORs for the association between screening participation and cervical 
cancer, with overall or age-group-specific corrections for selection bias
9.6.2 duration of sCreening effeCt
We explored the duration of any risk reduction associated with programme screening 
by defining exposure as participation in the round preceding the index invitation 
among those without a screening test at index (see Table 15; papers IV and V). 
Overall OR estimates were significant, 0.76 (0.59–0.99) for cervical cancer and 
0.48 (0.28–0.84) for death. Again, effect seemed to differ across age groups. A 
smear at the age of 55–69 was associated with a significantly reduced risk of both 




Age at invitation Corrected OR (95% CI)* Corrected OR (95% CI)*
All (25–69) 0.76 (0.59–0.99) 0.48 (0.28–0.84)
25–39 1.14 (0.73–1.78) 1.73 (0.44–6.80)
40–54 0.84 (0.56–1.26) 0.58 (0.28–1.23)
55–69 0.35 (0.20–0.62) 0.18 (0.05–0.62)
Table 15: Odds ratios for the association between cervical cancer or 
cervical cancer death and screening participation in the five-yearly 
invitation before index
* Corrected with participation rate 0.71 and self-selection factor 1.29 for 
incidence and 1.45 for death. Age-group specific ORs with death as an 
outcome were corrected by means of age-group-specific values.
9.6.3 duration of lowered risk after a negative sCreening test
The risk of cancer was analysed in overlapping one-year periods up to six years 
after a negative screening test (see Figure 5, presenting unpublished results). The 
OR remained below 1 for the whole period overall but developed differently in the 
different age groups. After 3.5 years, the OR was close to 1 for those screened as 
negative below the age of 40, whereas there was a more persistent reduction of risk 




Figure 5. Odds ratios of cervical cancer after a negative programme smear as compared to no such test since 
1990, by age group, estimated with conditional logistic regression in overlapping one-year periods, with 95% 
confidence intervals shaded grey. 
 
 
9.6.4  Effect of the last programme screen (IV and V) 
We estimated the OR associated with cervical cancer or death with diagnosis at any age over 65 and 
screening participation among those invited at age 65. For cervical cancer, the corrected OR for this 
association was 0.66 (0.29–1.50), and for death the corrected OR was 0.25 (0.03–2.20). In order to 
capture more cases in the analysis, we also estimated ORs for cervical cancer or cancer death 
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figure 5. Odds ratios of cervical cancer after a negative programme smear as compared to no such test 
since 1990, by age group, estimated with conditional logistic regression in overlapping one-year periods, 
with 95% confidence intervals shaded grey.
9.6.4 effeCt of the last programme sCreen (iv and v)
We estimated the OR associated with cervical cancer or death with diagnosis at 
any age over 65 and screening participation among those invited at age 65. For 
cervical cancer, the corrected OR for this association was 0.66 (0.29–1.50), and for 
death the corrected OR was 0.25 (0.03–2.20). In order to capture more cases in 
the analysis, we also estimated ORs for cervical cancer or cancer death associated 
with a last programme screen at the age of 55, 60, or 65, regardless of invitation 
status (see Table 16). Significant reductions in the risk of both cervical cancer and 
cervical cancer death with diagnosis at ages 66–80 were found with a last screen 
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at 60 and 65. There was a tendency for greater effect with a last test at a later age, 
particularly when the time of diagnosis was restricted to ages 71–80.
Age at last
screen Cervical cancer Cervical cancer death
Diagnosis at age 66–80 none* reference reference
  55 0.54 (0.26–1.14) 0.45 (0.09–2.17)
  60 0.49 (0.33–0.73) 0.41 (0.21–0.78)
  65 0.41 (0.23–0.74) 0.38 (0.16–0.90)
Diagnosis at age 71–80 none* reference reference
  55 0.77 (0.14–4.22) NA†
  60 0.47 (0.26–0.88) 0.43 (0.15–1.23)
  65 0.23 (0.08–0.63) 0.24 (0.06–1.00)
* No age-group programme screen at 55 or later registered in the study period
†  No cases.





The screening register’s coverage of cervical dysplasias and cancers was found to be 
excellent; hence, the information contained in the register is suitable for monitor-
ing activities. The grade of the lesion registered in the MSR was usually based on 
the first pathology report and therefore not always the same as the final diagnosis 
as registered in the FCR. For this reason, the sensitivity of the ICC diagnosis was 
only 69% even though all of these cases were recorded with some histological di-
agnosis. Of the comparison registers, the HDR had high coverage of cancers but 
lower coverage of dysplasias. There is a development of registering more types and 
an increasing proportion of health-care contacts in the HDR, and the coverage 
of the lower-grade dysplasias can be expected to improve further with time. The 
FCR receives active reports from many sources. Hence, especially for cancer, both 
coverage and accuracy are very high. The coverage of lesions with morphological 
codes included in the CIN3 category was found to be somewhat lower than that 
for cancer and than in the other registers. This is a result of both lingering under-
reporting to the FCR of these precancer lesions by clinicians and pathologists and, 
in this study context, also possible over-reporting in the registers contributing to 
the reference pool of diagnoses (MSR and HDR). Therefore, the real coverage of 
CIN3+ lesions in the FCR is probably higher than the 80% reported here, if all of 
these diagnoses should be verified by extraction from the original patient records 
in hospital archives. CIN1 and CIN2 lesions are not registered in the FCR.
If specific individual-level diagnoses are needed, especially with respect to the 
screen-detected cervical cancers, the data on MSR sensitivity (69%) and PPV (77%) 
suggest that data retrieval through linkage of health-care registers should be con-
sidered for accurate diagnoses.
There are no previous studies of the validity of the screening register data on 
histological diagnoses. The validity of the HDR data for cervical disease has not 
been examined, but there have been publications on the accuracy of cardiovascu-
lar diagnoses. Sensitivity for stroke and coronary heart disease in this register has 
been reported as 83–85% and the PPVs for these diagnoses as 83–92% (Pajunen 
et al. 2005, Tolonen et al. 2007). The sensitivity for ICC in our study was 81%, 
with a PPV of ICC diagnosis of 83%, roughly in line with the findings cited for 
cardiovascular diagnoses.
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The FCR is regarded as nearly exhaustive with regard to cancer diagnoses over-
all, thanks to the use of multiple notification sources (Teppo et al. 1994). In our 
study, which covered 10 years and 207 cases, there were only three cases of ICC 
missing from the original FCR records. One of these was originally registered as 
an unspecified female-genital-organ cancer. This translates to high coverage and 
sensitivity, both 99%, also specifically for the ICC diagnosis.
10.2 Cytology audit and test validity
For the screening service, the relevance of the cross-sectional validity measures 
presented in Table 9 may be somewhat limited, because they are derived from 
comparison of the ratings of two observers probably using variable criteria to call 
cytological smears. The validity estimates are, therefore, a composite of true sensi-
tivity and specificity, precision or inter-observer reproducibility, and also variable 
criteria used by the service screeners, reference laboratory, and expert panel in the 
cytodiagnosis. Here, low sensitivity indicates a difference between screening-service 
cytology and expert-panel cytology. Practical conclusions may be difficult to draw. 
We saw that, while a larger proportion of audit cases were abnormal according to 
final cytology, the differences in cytodiagnostic criteria also resulted in 3% of the 
controls being classified as needing a referral for colposcopy. If this were general-
ised to routine screening, this would mean a tripling of the colposcopies performed 
in the programme, where referral rates are currently around 1%. This may not be 
justifiable in light of the benefits on offer in terms of disease prevented. The study 
illustrates clearly the importance of including controls in any cytology audit. Because 
of the controls, it was evident that any increase in sensitivity of the cytodiagnosis 
requires that some of the specificity of the screening test be sacrificed.
Another, longitudinal, measure of sensitivity could be the proportion of CIN3+ 
screen-detected out of the total number of CIN3+ cases arising in the study period 
among those screened. This proportion amounted to 71% overall (1152/(1152-474)). 
Similarly, specificity can be defined as the proportion of those without CIN3+ in the 
study period who were not referred for colposcopy after their programme smear. 
This proportion was 99.2% ((944548-474)/(953610-474-1152)).
The reported sensitivity and specificity of cytology vary widely by setting. This 
is partly a function of the thresholds of both cytology (test threshold) and the gold 
standard (disease threshold). The gold, or reference, standard is usually histology 
but can also be expert-panel cytology or longitudinal disease outcomes. In ad-
dition, the inherent subjectivity of cytology as a test and also of a gold standard 
that relies on colposcopy and histology (both subjective) will introduce variability 
in the validity estimates observed in different studies. The specificity will further 
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suffer in particular from verification bias if only the test positives are assessed 
for the presence of disease. This is the case in service screening and also often in 
studies estimating the validity of cytology. If complete histological verification is 
used, the observed sensitivity will be lower and the specificity higher. In a meta-
analysis, the magnitude of the effect of verification bias was demonstrated by a 
decline in sensitivity when complete verification was used, from 0.67 to 0.52, 
and an increase in specificity, from 0.73 to 0.96 at a test threshold of LSIL+ and 
a disease threshold of CIN1+ (McCrory et al. 1999). The corresponding changes 
at disease threshold CIN2+ were 0.83 to 0.77 for sensitivity and 0.61 to 0.92 for 
specificity.
The variability in the validity of cytology was demonstrated by the ranges of 
sensitivity and specificity cited in a review of test-accuracy studies (Nanda et 
al. 2000). For those studies that used low-risk women presumably more repre-
sentative of the general screening population and complete- or random-sample 
verification of negative test results, the reported sensitivity still ranged from 30% 
to 87% and the specificity from 86% to 100% for a test threshold of LSIL+ and 
a disease threshold of CIN1+. For disease threshold CIN2-3+, the ranges were 
44% to 99% for sensitivity and 91% to 98% for specificity. Without these eligibil-
ity criteria in the studies reviewed, the variability was even more pronounced. 
The sensitivity results of the original screening-laboratory review with threshold 
LSIL+ in our cytology audit (i.e., 50% when the original six laboratories were 
used, in Paper II, or 56% when calculated from all seven laboratories participat-
ing in the audit – see Table 9; papers II and III) are best compared to an LSIL+/
CIN1 threshold combination if histology is used as the reference standard. These 
values sit comfortably in the middle of the range of 30–87% reported by Nanda 
and colleagues. However, the corresponding specificity value of 99% of the Finn-
ish screening-laboratory cytodiagnosis is at the higher end of the range 86–100% 
reported by Nanda et al. This observation is supported by the relatively low refer-
ral rates in the Finnish screening programme when compared to other European 
programmes, this despite demonstrably high effectiveness in cancer prevention 
(Ronco et al. 2009).
The choice of outcome in the cytology audit was CIN3+, which is a proxy for the 
invasive cervical cancer outcome that screening is to prevent. There is a limitation in 
that not all of the CIN3/AIS lesions would progress to cancer and, so, the number 
of audited ‘failures’ may be too high. However, there are some advantages to us-
ing CIN3+ instead of cancer as outcome in the audit. If there is a quality problem, 
it is desirable to know of this as early as possible, so that timely feedback can be 
produced for the service provider. By using CIN3+ as outcome in the evaluation, 
one can get audit results from larger numbers or earlier than would be possible 
with invasive cancer as audit outcome. Also, the results suggested that the false-
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negative proportions are very similar among the audited CIN3/AIS and cancer 
cases. It would seem that this outcome can safely be used if the follow-up time is 
appropriately chosen.
The false-negative rate observed in our audit was 35% (of archived slides of 
subsequent cervical cancer or interval CIN3+ cases), as reported in Paper II with 
data from six laboratories and 38% when the whole set of seven laboratories was 
used (see Table 8). Only one cytology audit was found in the literature review that 
included smears reported originally as both Pap I and Pap II without referral; there, 
the proportion of smears reviewed as clearly abnormal was 53% (Kenter et al. 1996). 
Most studies have included only clearly negative (i.e., Pap I) audit smears in the 
review. These studies, with ICC as outcome, observed clearly positive false-negative 
proportions, 19–31% (as shown in Table 3). The corresponding Pap I/LSIL+ result 
in our study was 24% ((11+49)/(42+210)) (see Table 8), which is in line with the 
values found in other programmes. By a third measure of false negativity, where 
negative or Pap I smears are reviewed for any abnormality, including borderline 
changes, the range of proportions found in previous publications was 21–71% (see 
Table 3). The range is wide probably in part because of variable ways of defining 
abnormal smears, as some studies may have included non-neoplastic abnormali-
ties whereas others may have included only cytological abnormalities indicative of 
dysplasia. Our estimate with application of these thresholds (Pap I/ASC-US+) was 
40%, well in line with these previously reported values.
On the assumption that the false-negative rates observed in the review material 
were representative of the whole audit-case population, the analytical failures of the 
screening test accounted for only 11% of the total CIN3+ burden in the screened 
population. 
As the cross-sectional sensitivity and also longitudinal clinical sensitivity and 
negative predictive value of HPV tests are favourable in comparison to cytology, 
a switch to HPV-based primary screening protocols would likely further reduce 
false-negative rates (Kitchener et al. 2011). The large variations in cytology tests’ 
validity between settings that arises from the subjective nature of the analysis would 
also be alleviated by automated and objective HPV analysis. The challenge of using 
HPV tests in primary screening is the handling of lower test specificity for cervical 
lesions that require treatment.
10.3 sCreening performanCe indiCators
There were large differences in all cross-sectional performance indicators among 
the seven screening laboratories in the cytology audit. In general, the differences 
can be interpreted as representing laboratory policies of reporting cytology with 
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differential relative emphasis on the sensitivity vs. specificity of the cytodiagnosis. It 
is also possible that risk factors, mainly HPV prevalence, have been variable across 
the regions covered by the laboratories (Lehtinen et al. 2006). The CIN detection 
profile, which can be described by the ratio between CIN1 and CIN3+ detected by 
screening, reflects the reporting policy of the laboratory. The CIN1/CIN3+ ratio 
ranged from 0.2 to 2.4, with an average of 1.0. Specificity-oriented laboratories 
have a low CIN1/CIN3+ ratio, low referral rate, high test specificity, and high PPV 
(laboratories E and G), while the opposite is true for laboratories that prioritise 
sensitivity (laboratories A, B, and C) (Paper III). In theory, operating a screening 
programme with high sensitivity should be more effective at removing precancer-
ous lesions from the population and hence preventing cervical cancer incidence 
and mortality. Orientation toward high specificity, on the other hand, should limit 
the adverse effects of screening such as the psychological burden of positive test 
results and number of colposcopies, biopsies, and possibly also conisations. How-
ever, population-based effects are strongly influenced also by screening uptake by 
women at risk and the quality of follow-up and management of screen positives.
The audit-case rate among screened women varied to a much lesser degree than 
the cross-sectional indicators did. No significant heterogeneity was observed in this 
measure upon formal testing. 
Considerable differences in performance indicators have been reported between 
screening centres within individual countries (Kotaniemi-Talonen et al. 2007, Blanks 
2008). When one compares indicators from national programmes, the differences 
are even greater (Ronco et al. 2009). For example, the aggregate data for Italian 
screening programmes in 2008 indicated an overall referral rate of 2.4% with a PPV 
of referral for CIN2+ lesions of 16% (Ronco et al. 2010b), compared to the referral 
rate of 1.0% and PPV for CIN2+ of 25% observed in our study overall (Paper III). 
The detection rates of these two programmes differ less from each other, 3.1/1000 
screened women in Italy compared to 2.4/1000 in Finland. In the Netherlands, a 
1.4% referral rate produced a PPV of 42% for CIN2+ lesions and a detection rate 
for CIN2+ of 6.4/1000. Corresponding values for the English programme were a 
referral rate of 2.7%, PPV of 49%, and CIN2+ detection rate of 11/1000 (Ronco et 
al. 2009). It is difficult to draw conclusions from these comparisons. Not only do 
the values depend on the criteria used for the cytodiagnosis, but also the disease 
prevalence, thresholds for intensified screening recommendations and referral for 
colposcopy, quality of histological verification, compliance rates, and magnitude of 
any opportunistic screening activity will have an impact. Significant opportunistic 
screening occurs in Italy and Finland (Ronco et al. 2010a, THL 2011), whilst this 
activity is now far less commonplace in the Netherlands, because of withdrawal of 
subsidies. Opportunistic screening may also affect the number of potential false-
negative audit cases observed in a population by detecting cases of severe dysplasia 
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that would have regressed before the next scheduled programmatic screening event. 
Lifetime regression rates of CIN3 or equivalent lesions have been estimated in co-
hort studies to be between 12% and 32% (Syrjänen 2009); in the five-year interval 
between programme invitations, the proportion should be much less.
There are no recommended target values for performance indicators in cervical 
screening as there are for breast cancer screening. Because of the complexity of the 
screening process, from identification and composition of the target population and 
its disease and risk factors’ prevalence to the quality of diagnostic confirmation, 
therapy, and follow-up, the relevance of any recommendations may be restricted 
to individual programmes or regions. This difficulty applies to the optimal values 
of referral rates, CIN detection profiles, and related indicators while it is clear that 
the attendance rate in the invitational screening programme and compliance with 
referral recommendations and follow-up should be as high as possible.
Even though the reporting policies were found to vary to a large degree between 
laboratories in the screening programme, no significant variation was observed in 
the rates of missed progressive lesions. It is possible that the differences in test valid-
ity and detection rates for progressive lesions are smaller than for non-progressive 
lesions. It is also possible that intensified programme screening and opportunistic 
screening in the interval between age-group invitations catch missed lesions before 
they have a chance to progress to invasive or pre-invasive disease. However, it is 
important to continue to produce regular feedback by using outcome information 
from follow-up after screening in order to harmonise reporting and recommenda-
tion policies and to avoid unnecessary adverse psychological and physical effects 
of the follow-up and management of smears reported as abnormal.
10.4 audit of sCreening history
10.4.1 mode of deteCtion
Screen-detected cancers have a favourable prognosis when compared to sympto-
matic cancers (van der Aa et al. 2008, Andrae et al. 2012), because diagnosis in 
the preclinical phase allows more successful and often less aggressive radical and 
curative treatment even after adjustment for stage at presentation. On the other 
hand, screen-detected cancers should, as should all other cancers, be considered 
failures of the screening programme, which primarily aims to identify and treat 
precancerous lesions in order to prevent the development of invasive disease. Stage 
at diagnosis is a separate but related dimension. Screen-detected cancers (non-
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symptomatic cancers) are more often of lower stage than symptomatic cancers, and 
the microinvasive stage is nearly always screen-detected. Cancers diagnosed at the 
microinvasive stage very rarely proceed to cause death in settings with adequate 
health-care capabilities (Paper V). Therefore, some experts consider only frankly 
invasive (stage IB+) cancers to be failures of the screening programme.
Screen-detected cancers constituted 11% of the total cancer burden in Finland in 
2000–2009. Van der Aa et al. (2008) reported that 35% of the cancers diagnosed 
in the Netherlands were screen-detected in the age groups targeted by screening in 
1992–2001. The equivalent proportion in our setting was 19% when the denominator 
is restricted to those invited to take part in the programme (Paper IV), still far below 
the Dutch figure. The extent of opportunistic screening hampers the comparison, 
as the distinction of screen-detected and symptomatic cancers only holds when all 
screening smears are in the programme. Certainly, non-symptomatic cancers are 
diagnosed outside the Finnish programme, as indicated by the many microinvasive 
carcinomas found among nonattenders and during the between-screening intervals 
(Paper IV). The Dutch study did not report microinvasive carcinomas separately. 
High proportions of screen-detection have been reported from the UK. Of 133 can-
cers diagnosed in two London boroughs in 1999–2007, 49% were screen-detected 
(Herbert et al. 2010), and from among 382 cancers diagnosed in Southampton in 
1985–1996, 33% were screen-detected (Herbert et al. 2009a). In the Swedish au-
dit, 25% of all cancers (Andrae et al. 2008), and 32% of cancers at screening ages 
(Andrae et al. 2012) diagnosed in 1999–2001 were screen-detected. In addition to 
opportunistic screening, the definition applied for screen-detection may account for 
part of the difference observed. We have used the presence of a referral for colpos-
copy within 12 months before diagnosis as evidence of screen-detection, as recom-
mended in the European guidelines (Arbyn et al. 2008a). In the Netherlands, the 
pathology and cytology register PALGA can provide this information (Casparie et 
al. 2007). The Swedish audit defined screen-detection as a (presumably abnormal) 
smear 1–6 months before diagnosis, and the UK audits have used clinical criteria 
as determinants of screen-detection (Herbert et al. 2009b).
No information was available for comparison with respect to deaths due to 
screen-detected cancers as a proportion of all deaths due to cervical cancer. At 
3%, this proportion was much lower than for all cervical cancers in our material.
10.4.2 preventive sCreening status
In order to achieve high effects of screening on incidence and mortality, coverage 
and attendance are a priority in all screening programmes and usually also consti-
tute the most important area for improvement in the effectiveness of established 
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programmes. Coverage by invitation is high in the Finnish programme. The current 
coverage is almost complete: 98–100% of those at the recommended target ages 
in 2009 (see Table 5), but historically there has been slightly more variation, with 
6–7% of women belonging to the currently recommended age groups lacking a 
registered invitation in the audit study period, 1990–2009. However, this figure is 
an overestimate, because it includes women registered as residents in the interval 
between index invitation and date of diagnosis. In addition, invitations have been 
under-reported to the centralised mass screening registry in a small number of 
cases, inflating the figure further. The proportion of cancers diagnosed in women 
after the last invitation was 32%, and more than half of the deaths were attributed 
to these cancers. In other well-established programmes, the equivalent proportion 
was similar or slightly lower. In the Swedish audit, 25% of cancers were diagnosed 
at ages above 65, corresponding to time after the last screening round (Andrae et al. 
2008). In the Southampton audit, 30% of cancers were diagnosed in this age group 
(Herbert et al. 2009a). The proportion can be expected to increase as screening 
removes cancers at the target ages.
The attendance rate was 71% overall in the study period, with a very slow de-
terioration observable over the past decade, mainly in ages under 40. The second 
largest group by preventive screening status at index round among both cancers and 
cancer deaths was that of the non-attenders. This group accounted for 32% of the 
incident cancers and 25% of the deaths, indicating that further efforts to improve 
attendance are needed. Those developing cancer despite attending screening are 
of special concern in the screening-service audit and, especially, for the feedback to 
screening laboratories. In the previously published screening-history audits listed 
in Table 2, the range of the proportion of cancers diagnosed after participation in 
screening in a comparable defined period of time was 19–54%. Our result of 24% is 
at the lower end of this range. For deaths in our study, the corresponding proportion 
was 14%. Within this category, we can further identify the potentially false-negative 
screening tests, which amounted to 16% of cancers and 13% of deaths, as compared 
to the range of 9–37% in previous studies (again, see Table 2).
There were only four cancers diagnosed after a negative HPV screen, 0.3% of 
all cancers, compared to 1.0% of controls. The high sensitivity and NPV of HPV 
testing is especially visible in the corresponding numbers among deaths: no deaths 
were observed due to cancers diagnosed after a negative HPV screening test, com-
pared to 15, or 0.5%, of the controls having a negative HPV test at index screen. 
The difference in the proportion of negative HPV tests at index between the two 
control populations is due to the difference in the distribution of diagnosis over 
calendar time relative to the HPV trial. Diagnoses were made in 2000–2009 in 
the incidence data and 1990–2009 among the deaths, and the HPV DNA test was 
introduced in 2003.
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Compliance with referral seems excellent; only one case of non-compliance was 
found among the cases and another among the controls. A similar observation was 
made previously for an earlier period of screening (Viikki et al. 2000). Management 
failures were relatively rare. Under 1% of all cancer diagnoses had a colposcopy at 
index screen. There were no deaths due to cancers diagnosed after a colposcopy in 
the index round, no matter the histological outcome of the visit. In comparison, a 
systematic review of screening-history audits reported an average of 12% of cancer 
cases as failures of follow-up after a truly abnormal smear prior to diagnosis. Indi-
vidual studies reported proportions ranging from 3.2% to 50% (Spence et al. 2007).
These data on the screening history of cases justify further enquiry into the vi-
ability of extending screening invitations also to women aged 65, as 32% of cancers 
and 53% of deaths have diagnoses after this age. As expected, non-attenders con-
stitute the other important focal point for improvement, with 32% of cancer cases 
and 25% of cancer deaths belonging to this category. Efforts to increase attend-
ance are already under way. For instance, promising results have been achieved by 
sending self-sampling kits to women who fail to participate (Virtanen et al. 2011). 
Improving the sensitivity of the screening test can have a theoretical maximum ef-
fect of further reducing incidence by 17% and mortality by 13% (corresponding to 
the proportions of cases having a negative screening test at index).
10.5 effeCts of partiCipation in sCreening
10.5.1 effeCtiveness of organised sCreening
The case–control analysis of screening exposure estimated the association of screen-
ing participation with any reduction in risk of either cervical cancer or death from 
cervical cancer with a diagnosis in the five-year screening interval up to and includ-
ing any screen-detected cancers in the following screening event. Only participation 
in the organised screening programme counted toward screening exposure. It is 
likely that some of the women classified as non-exposed to programme screening 
had been opportunistically screened during the window of exposure (THL 2011). 
The risks of cervical cancer and cervical cancer death of programme non-attenders 
may therefore be somewhat lower than would be the case without opportunis-
tic screening, leading, in turn, to lower estimates of the risk reduction associated 
with programme screening attendance. Bearing in mind that the estimates refer 
to programmatic screening attendance against a backdrop of opportunistic screen-
ing, we found that a single screening test in the programme reduced the risk of 
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cervical cancer of any morphological type or stage in the next five-year interval by 
47% overall. The corresponding reduction in the risk of death with diagnosis in 
the same period was 66%. However, the effect was strongly age-dependent, with 
smaller reductions for participation before the age of 40 and uniformly large risk 
reductions associated with participation at age 40 and above. A tendency toward 
lower risk reduction with lower age was also observed within the age range 25–39.
Age-dependent effectiveness or efficacy of screening has recently been reported 
also from other screening programmes. A large audit from the UK reported highly 
age-dependent ORs for participation in screening. Screening at ages 22–24 had 
no effect with an OR over 1, but after this age the OR rapidly dropped such that at 
30–37, screening participation was associated with a reduction in risk of 43–60% 
and at 40–64 the reduction in risk was 64–82% (Sasieni et al. 2009a). Two case–
control studies from Italy have reported lower effects of screening in women under 
the age of 40. A study describing the programme in Trento found no association 
with screening participation for women under 40 for cancers of any morphologi-
cal type (OR: 1.00, 95% CI: 0.18–5.65) or for squamouscell cancers (OR: 2.03, CI: 
0.20–20.4), whereas the point estimate indicated a lowered risk of adenocarcinomas 
(OR: 0.25, 0.02–4.0) (Crocetti et al. 2007). The small numbers render these esti-
mates unreliable, but they suggest a pattern similar to that found in our material. 
Data from Florence also suggested smaller effects for screening participation in the 
previous five years at ages under 40 although still significant and considerable (OR: 
0.32, CI: 0.11–0.95) (Zappa et al. 2004). The ORs for the other age groups were 0.11 
(0.04–0.33) for women aged 40–49, 0.08 (0.02–0.31) for women aged 50–59, and 
0.22 (0.06–0.83) for women 60–69. Lower ORs of the association of any screening 
participation and cancer diagnosed under the age of 30 were observed in South 
Africa, as compared to diagnosis at ages 30 and above (OR: 0.7, CI: 0.3–2.1 versus 
OR: 0.3, CI: 0.2–0.4) (Hoffman et al. 2003). In the Swedish audit, equal effects 
were reported initially for screening participation across all age groups (Andrae et 
al. 2008). In a subsequent discussion between the authors of the Swedish and the 
UK audits, additional analyses were presented wherein the effect on IB+ cancers 
diagnosed at age 27–29 persisted but no effect could be demonstrated for women 
aged 23–26 (Andrae et al. 2009). No corrections for self-selection bias were made 
in any of the above studies.
The trends for cervical cancer in Finland show that the most dramatic declines 
in incidence since the start of the programme (with rollout during the 1960s) have 
been observed for ages 40–49 (from 42/100,000 in 1965 to 6/100,000 in 1990) 
and 50–59 (from 48/100,000 in 1965 to 7/100,000 in 1990) (see Figure 6). A 
smaller but still substantial decline can be seen for ages 30–39 (15/100,000 to 
4/100,000), albeit from a lower level, but incidence was already falling in this age 
group when the screening programme was launched, in contrast with the 40–59 
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age group, for which incidence was increasing. Also, since 1990, incidence has again 
been increasing for ages below 40, while decreasing trends have continued in all 
other age groups. It seems likely that there has been some impact of screening on 
incidence among those below 40 also but that this effect is smaller than that in 
older women. The current case–control data support this view.
 
figure 6.
The reasons for the weak association between screening attendance and cervical 
cancer risk at younger ages are subject to speculation. It is clear that HPV infection 
and low-grade dysplastic lesions are more prevalent at younger ages, but detection 
and treatment of these lesions appear not to affect the risk of cervical cancer or 
death to the same degree as at a later age. The most plausible explanation is that the 
natural history of these lesions differs by age. In this scenario, most cases of CIN2+ 
detected at a young age would not progress to invasive disease before the next screen-
ing invitation. The rare cases that do progress develop rapidly and offer only small 
possibilities of detection during their short precancerous stage (Sasieni et al. 2009). 
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Similar patterns of age-specific effect were seen in the mortality data. Participation 
in screening at the ages of 25–39 reduced the risk of death by 30%, but the esti-
mate was non-significant. In contrast, significant effect estimates of 67% and 71% 
were observed for participation at 40–54 and 55–69. Some previous studies have 
reported screening effects on mortality, but none have investigated age-specific ef-
fects. Generally, the effect on mortality seems to be greater, probably because of the 
additional effect of likely diagnosis at an earlier stage in the disease in the screened 
population. A study from Scotland reported an OR of 4.0 (2.1–8.5) for the association 
of death from cervical cancer and no previous screening tests as compared with 1–2 
previous screening tests and a corresponding OR for the association with cervical 
cancer diagnosis of 2.8 (2.0–4.1) (Macgregor et al. 1994). A Japanese study with 
data from Osaka observed an OR of 0.22 (0.03–1.95) for the association between 
death from cervical cancer and screening participation in the 10 years preceding 
diagnosis and a corresponding OR of 0.41 (0.13–1.29) for cancer incidence (Sobue 
et al. 1990). At least one earlier cohort study found a similar relationship between 
effects on incidence and mortality (Magnus et al. 1987).
figure 7.
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Reduction in mortality after introduction of the screening programme does not 
show such clear differences as can be seen in the incidence trends. Large declines 
can be observed across all ages (see Figure 7). The difference is found in the start 
of the downward trend, which occurs progressively later as the age band increases. 
Mortality is affected not only by prevention of cancer by screening but also by better 
treatment and management, along with earlier diagnosis.
10.5.2 self-seleCtion bias
The results of the current study point to the large difference that correction for self-
selection bias can make in the observed risk reductions associated with participa-
tion in screening. The estimates of this bias were based mainly on results for those 
invited to screening at the age of 25 and 65, and to a lesser degree those invited 
at 30 and 60. These are the ages where invitation coverage has been variable and 
both uninvited and invited women were found. Ages 35–55 have been covered well 
by screening invitations, and the contribution of these age groups to the estimate 
of the self-selection bias was therefore limited. There were not enough cases in the 
separate cells for exposure+outcome combinations for age-specific estimation of 
the selection bias, but if there are large differentials in this bias, the comparison 
of screening effect between different ages at exposure could be jeopardised. In 
addition to overall corrections, we produced age-specific self-selection factors by 
adjusting for age-specific participation rates. This resulted in a smaller correction 
at young ages when participation has been lower and a larger correction at the 
ages of 55 and 60 when participation in the Finnish programme has been above 
average. However, using age-specific self-selection factors did not significantly alter 
the results: the screening effect was still clearly smaller for women under 40 and 
was small or absent for screening at 25.
The magnitude of the self-selection bias can be compared to that in early cohort 
studies for which uninvited populations were available. A Finnish study compared 
non-participating women’s results with expected risks from the time before screen-
ing and found a relative risk of 1.6 (Hakama and Rasanen-Virtanen 1976). Also, a 
Norwegian study observed a relative risk of 1.6 in invited but unscreened women 
in comparison to neighbouring regions without screening (Magnus et al. 1987). A 
third cohort study used data from the programme in British Columbia and observed 
a relative risk of 1.1 for unscreened women (Fidler et al. 1968). Our estimate for the 
risk of non-participants as compared to non-invited women was 1.29 for stage-IA+ 
cancers and 1.45 for IB+ cancers. These values are somewhat lower than the ratio 
found in the cohort study from Finland, but the setting also is very different. Par-
ticipation rates in the early programme were much higher (85%) than during our 
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study period. If most of the populace participates in screening, the small proportion 
not participating may well be a particularly high-risk group of women. If, on the 
other hand, the group of non-participants is large and heterogeneous, the difference 
in risk may be smaller. The risk profile of the population was also different from 
that in the current setting, in which some of the women failing to participate in the 
index screen may have participated in previous screens, and also overall risks in the 
population are lower. Opportunistic screening occurs also in the nonparticipating 
part of the population and may dilute not only the effect of screening but also the 
baseline risk ratio, because of self-selection into programme participants and non-
participants. Indeed, lifetime coverage of the Pap test has been estimated at 98% 
(Anttila and Nieminen 2007) when opportunistic smears are included.
The self-selection factor for estimated effects on mortality was derived from the 
incidence data on stage-IB+ cancers. We could not estimate a self-selection factor 
specifically for mortality, since there were very few deaths with a diagnosis after 
invitation at ages 25–29 and 65–69. We excluded the microinvasive carcinomas 
from this analysis, since they contribute very little to cervical cancer mortality.
Case–control studies estimate effectiveness as reduction in the risk of disease 
associated with the intervention – in this case, participation in screening. Participa-
tion in multiple screening events over a lifetime will be associated with incremental 
reductions in risk, as the duration of lowered risk usually exceeds the screening 
interval. In earlier studies, exposure has often been defined as ever-screened ver-
sus never-screened, and here the total of the incremental effects may be visible. 
In contrast, many of the more recent studies, ours included, seek to estimate ef-
fectiveness as the risk reduction associated with a single participation event in a 
narrower window of exposure. In the latter case, the estimate will be the average 
risk reduction effected by that one screening event, in a population with various 
types of previous screening history. In an established screening programme, the 
amount of previous screening is necessarily correlated with age: at older ages, those 
who participate in screening probably have a larger number of previous screens and 
the potential for any additional incremental gains may be smaller than amongst 
younger women, all other things being equal. Therefore, it is possible that a valid 
comparison of screening effects across age groups would require corrections of 
self-selection bias that are based on directly observed age-specific risk ratios for 
those not participating as compared to those not invited. In this study, we were 
not able to use this method, on account of a lack of power, and had to rely on ob-
served overall self-selection factors and age-specifically adjusted factors based on 
the observed participation rates only. No other studies have attempted to quantify 
age-specific self-selection factors by the methods we have employed, much less by 
direct observation, so it is difficult to say whether – and, if so, how much – the 
age-group comparison would be affected.
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10.5.3 duration of effeCt
The duration of any protective effects of screening participation was explored with 
definition of exposure as participation in the screening round before index. With a 
screening interval of five years, the window of exposure thus was located 5–10 years 
before diagnosis. As expected, the observed reduction in incidence and mortality 
was less than in the main analysis with exposure defined as participation in the 
index screen. However, the risk reductions were still clear and significant overall, 
with a larger reduction in mortality than in incidence. The relationship of effect 
estimates for incidence and mortality was the same with both definitions of exposure 
(ratio of ORs: 1.6). Also, the decline in effect over time was similar between the two 
outcomes, with the value of the OR for participation 5–10 years before diagnosis 
divided by the OR for participation 0–5 years before diagnosis being 1.4 for both 
incidence and mortality. However, the duration of the protective effect differed 
between age groups. In the oldest age group, with invitation at ages 55–69, there 
was very little to no decline in the reduction in risk over the time period examined, 
suggesting that screening at this age offers a long-lasting protective effect. Screening 
at the ages of 40–54 yielded point estimates below unity, but the results were non-
significant and the difference with the effect of index screen exposure was clear. In 
the youngest age group, no remaining effect was observed.
An Italian case–control evaluation also found shorter protection for women 
under 40 than for women 40 or over when exposure was defined as any smear 
(positive or negative) and duration as either less than or more than three or 
five years before diagnosis (Zappa et al. 2004). A case–control study from the 
UK followed the evolution of odds ratios after an operationally negative smear 
for up to 6.5 years (Sasieni et al. 2003). There were clear differences in the de-
velopment of risk after the negative smear in the UK study. Risk reached unity 
after three years for women aged 20–39, approached the background risk level 
after five years for women aged 40–54, and remained at a significant 0.5 at six 
years for women aged 55–69. Their results are very much in line with ours with 
respect to the duration of effect, even though the approach of using negative 
smears as exposure does not, in fact, describe screening effect, as discussed in 
the next section.
10.5.4 duration of low risk after negative sCreening results
The duration of low risk after a negative screen in the Finnish setting has been as-
sessed previously with screening information from 1971–1976 (Viikki et al. 1999). 
That cohort study examined the risk of CIN3 and cancer and found standardised 
incidence ratios of 0.5 to 0.6 with follow-up until 1994. The lowered relative risk 
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associated with a negative smear was found to become even lower with advancing 
age, which is consistent with our findings.
Even though studies of screening efficacy and effectiveness have sometimes de-
fined exposure in terms of negative screening tests, that approach is not conceptually 
unproblematic. The only way in which screening can produce an effect is by leading 
to the treatment of precancerous lesions and thereby halting the development of 
cancer. For this to happen, the screening test must detect the abnormality – i.e., 
be positive. Hence, only a positive screening test can have an impact on cancer 
incidence and mortality. The risk reduction observed after a negative screening 
test is caused by the selection of a low-risk population. When reduced risk after a 
negative screening test is observed, the fact provides evidence of the discrimina-
tory properties of the test, which, in turn, can be assumed to result in the correct 
identification and treatment of women at higher risk. This approach to evaluating 
effect is indirect, and many methodology-focused papers have advised against it 
(Knox 1991, Weiss 1994, Cronin et al. 1998, Zappa and Ciatto 2000). However, 
the approach is appropriate if the objective is to evaluate the negative predictive 
value of a screening test – for example, for the estimation of appropriate screen-
ing intervals. In this case, selection bias is not an issue, since selection is precisely 
the parameter of interest.
Our results for the duration of low risk after a negative screen can be compared 
to those reported from the UK (Sasieni et al. 2003), where the results are presented 
for age groups similar to ours. The evolution of the OR over time in the various age 
groups is also very similar between these two studies; perhaps a slightly better NPV 
is suggested in the Finnish programme, particularly for the 25–39 and 40–54 age 
groups, but differences are small. These results prompted the authors of the UK 
study to propose triennial screening for women aged 25–49 and screening every 
five years for women of 50 and over. Similar policy considerations were applied in 
the Swedish programme. Even though our results also corroborate a shorter dura-
tion of low risk after a negative screen in young women, this does not necessarily 
mean that the associated age group should be tested more intensively. If little or no 
protective effect of screening can be demonstrated in this age group, an intensified 
screening frequency will only increase adverse effects without providing additional 
protection. For this reason, it is extremely important not to base policy decisions on 
the NPV of screening alone. One should also consider real effectiveness estimates 
and balance the potential benefits and harms. Compared with increasing the screen-
ing frequency for young women with their high prevalence and turnover of HPV 
infections and intraepithelial lesions, prophylactic vaccination probably provides 
a better avenue for addressing cervical cancer risk in women in the younger age 
groups (Yamamoto et al. 2012).
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10.5.5 sCreening at the age of 65
The currently recommended target ages for screening in Finland are 30–60, and 
these ages are now well covered by invitations at five-year intervals (see Table 5). 
Some municipalities have also chosen to invite women at the age of 25 and 65, pro-
viding us with an opportunity to evaluate the effect of screening participation also 
at these ages. As the burden of both incidence and mortality lies to a large extent 
with the ages after the last recommended screening round, screening effectiveness 
at 65 is of particular interest. A similar effect on incidence in the following five-year 
period was observed for participation in a single screen at 65 as compared to that 
of participation at 60, but the small numbers meant that the confidence intervals 
included 1. In an attempt to include more observations in the estimate, we also 
analysed the effect of participation at 65 on the risk of cancer or death at any point 
beyond that age. The resulting corrected OR of the association with cervical cancer 
was 0.66 (0.29–1.50) for incidence and 0.25 (0.03–2.20) for death, indicative of 
an additional effect but still non-significant. We further enhanced the observations 
in the analysis by comparing participants to those not participating, regardless of 
invitation status. When screening participation at 55, 60, or 65 was compared to 
no screening participation at 55 or later, significant ORs were observed for both 
incidence and mortality for screens at 60 and 65. In addition, there was a trend of 
increasing effect with later screens. We observed risk reductions of 59% (OR: 0.41, 
CI: 0.23–0.74) and 62% (OR: 0.38, CI: 0.16–0.90) for incidence and mortality 
associated with a screen at 65 and diagnosis at the ages of 66–80. The effects in 
comparison to no screen at 55 or later were even larger if the outcome was defined 
as age at diagnosis of 71–80. This is the age band for which the frequency of cervi-
cal cancers currently peaks.
The duration of low risk of cervical intraepithelial lesions and cancer is longer 
after a negative HPV test than it is after negative cytology (Castle et al. 2012). 
This period is also age-dependent, such that negative HPV tests predict low risk 
for a longer period of time at older ages (Schiffman et al. 2011). In addition, HPV 
prevalence falls with age, while the proportion of cytological changes that are reac-
tive may increase (Leinonen et al. 2009). These facts could provide a reasonable 
foundation for a so-called exit test after which only those with positive HPV tests 
would remain in the programme.
10.6 strengths and limitations
The Finnish setting provides several major advantages for the evaluation of screen-
ing activities and impacts. Comprehensive national registers are available for ac-
curate linkage by unique personal identifier between data on screening invitations, 
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tests, and verifications in the screening register and the outcomes for the whole 
population in the cancer register. The registers have good coverage and accuracy 
of information for this purpose. Also, the programme is well-established; the whole 
population has been uniformly covered.
There was little possibility of verification bias in the cytology audit, as all smears 
were evaluated by two raters. The review of smears was performed blinded to case 
status and previous cytodiagnosis, and case smears were randomly mixed with 
control smears. Controls ensured additionally that information on the specificity 
of rereading and also on the gold standard was available. It is possible that, despite 
blinding, the knowledge of reviewing audit smears may have led to increased vigi-
lance and possibly over-calling relative to a normal screening situation. The LSIL+ 
proportion of controls in the original laboratory results was 1.5%, not very different 
from the 1.0% seen in routine practice. These values suggest a small loss of speci-
ficity (perhaps with a concomitant increase in sensitivity) at most. Correlation of 
review results between screening and reference laboratories was moderate. It seems 
that an expert panel’s review is needed, to establish a good reference standard for 
cytology. Single-reference-laboratory review is not reliable, because of the inherent 
interobserver variability of cytodiagnosis.
It is important to ensure that cases and controls have equal opportunity for 
screening exposure in the evaluation of screening effectiveness. The Finnish screen-
ing programme offers an advantage in this respect, since invitations are sent mainly 
to women of an age divisible by 5, and all eligible women are invited at these ages, 
regardless of any preceding screening tests. In many previously published studies, 
screening exposure has been defined with the exclusion of a 6–12-month period 
before diagnosis, in order to exclude any diagnostic smears, or smears taken be-
cause of symptoms. Because we used only invitational smears as exposure, we 
did not need to make this exclusion. In addition, we were able to identify screens 
leading to the detection of cancer and could then index the screening exposure to 
the preceding five-yearly screening invitation event for the screen-detected case 
and associated controls.
For the first time in a case–control study for the evaluation of cervical cancer 
screening effectiveness, corrections for self-selection bias were applied. We found 
the bias to have a considerable impact on the point estimates. We were also able 
to adjust the overall selection bias for age-specific participation rates so that com-
parison of effectiveness between age groups was more reliable. However, we were 
not able to measure the selection bias directly in the individual age groups, mainly 
because of the high coverage of the core target ages of the programme. We were 
also forced to use a selection bias estimated for stage-IB+ cancer as outcome in the 
corrections for mortality effect, again on account of the small numbers of observa-
tions when we used death as outcome. For these reasons, even though it is clear 
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that participation in screening does cause selection into participants at a lower 
baseline risk and non-participants at a higher baseline risk, the point estimates for 
this selection must be considered approximate. However, we are confident that the 
corrections used are sufficiently accurate not to invalidate our findings.
Opportunistic smears represent the main limitation in this setting. It has been 
estimated that two thirds of all screening tests are opportunistic. These smears 
are not yet centrally registered and cannot currently be taken into account in the 
evaluation of the effectiveness of screening. Hence, any effectiveness estimates are 
strictly descriptive of organised-screening participation against a backdrop of con-
siderable opportunistic activity. For example, the observation that participation in 
the organised screening programme at age 25 does not influence the risk of cancer 
or death does not necessarily mean that the screening test overall has no effect at 
this age. It is possible that the effect was partly obscured by opportunistic screening 
of non-participants. However, also women 40 and above use extensive opportun-
istic screening services and yet large risk reductions were seen after programme 
participation at these ages. A recent report commissioned by THL on the burden 
and prevention of HPV disease showed that coverage of invitational-screening non-
participants by opportunistic smears decreased with increasing age (THL 2011). 
On the other hand, the proportion of participants in programme screening who 
were covered by opportunistic screening tests in a fiveyear period was fairly con-
stant (50%) across the invited age groups. It is clear that differential intensity of 
opportunistic screening cannot entirely account for the large differences observed 
in programme screening’s effectiveness across age groups.
10.7 summary and impliCations
Data on screen-detected cervical lesions were compared across three health-care 
registers: the mass screening register, the cancer register, and the hospital discharge 
register. There was considerable agreement over the three registers despite their 
different uses and data collection methods. The mass screening register data on 
histological diagnoses have high coverage and are useful for statistical and moni-
toring purposes related to the screening programme. However, for use of the most 
accurate information available, there are grounds for considering the collection of 
data on diagnoses and management through systematic data retrieval that involves 
linkage with other health-care registers. The cancer register data on cervical cancers 
demonstrated a very high level of completeness, but additional information might be 
gained through consultation of the other registers with respect to CIN3/AIS lesions.
Only a small proportion of CIN3+ cases, cervical cancers in particular, were 
due to analytical screen failure. The validity of the cytodiagnosis in the screening 
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laboratories involved in the screening programme was satisfactory in the setting of 
very low cancer incidence and mortality having been reached in the target popula-
tion and low referral rates overall. However, the reproducibility of the cytology is 
only moderate, and care must be taken so that specificity variations do not produce 
inequalities in adverse effects and in the cost of screening between regions served 
by different laboratories. Large variations have been observed in the burden of 
cancer of the cervix between countries and in historical trends. Hence, regular and 
comprehensive audits should be performed to monitor the screening process and 
optimise the performance of cytology. 
Large variations by laboratory were observed in performance indicators describ-
ing the screening process. Despite the apparent differences in reporting policies, 
no significant variation in the rates of missed progressive lesions could be dem-
onstrated. The programme functions with a good and comparable effect across 
geographical regions. This means that the monitoring of performance indicators 
alone is not enough; evaluations and probably also audits of longitudinal outcome 
measures are needed for ensuring a screening service of high quality. Information 
provided by performance indicators is important too, and feedback on reporting 
criteria for cytology is clearly indicated if we are to harmonise the screening service 
and avoid adverse effects and unnecessary costs.
A single screening episode within the organised screening programme reduces 
the risk of cervical cancer by half. The reduction in the risk of death from cervical 
cancer is even larger. However, this effect is age-dependent such that screening 
participation at ages below 40 is associated with a clearly smaller risk reduction 
than participation at age 40 and above. No incidence effect was observed at the 
age of 25, but effect on mortality could not be estimated, because of the small 
numbers involved. Opportunistic screening is, and has been, in widespread use in 
the population, especially at younger ages, and, in order for final conclusions to be 
drawn on the effect of screening at ages below 30, evaluations that take these tests 
too into consideration are needed.
The duration of reduced risk was also age-dependent and increased with age. It 
seems that screening participation at age 65 would yield additional incidence and 
mortality benefits at the ages at which advanced disease and death from cervical 
cancer are currently most frequent. 
The remaining cervical cancer cases and deaths in a well-screened population 
occur to a large extent more than five years after the last screening invitation. 
Cancers and, especially, deaths from cervical cancer with a diagnosis before first 
invitation, are rare. These observations in combination with the findings on age-
specific effectiveness may be useful for the planning of future modifications to the 
screening programme. Another group of concern is that of the invited nonattenders, 
which contributes a quarter to a third of all cancer cases and deaths. Continuing 
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efforts are needed to ensure that the screening programme reaches in particular 
that currently noncompliant group of women that has been shown to demonstrate 
a higher baseline risk of cervical cancer. Cancers arising after negative screening 
tests constitute a smaller proportion of cancers and cancer deaths, but some benefit 
could also be gained through improved sensitivity of the screening test, provided 
that specificity can be maintained.
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11 ConClusions
• The quality and especially the coverage of the screening register with 
respect to histopathological diagnoses of screen-detected lesions are suffi-
ciently high for the production of statistics and monitoring data. However, 
the accuracy of diagnostic information can be improved by data retrieval 
from other health-care registers. In particular, linkage to the cancer reg-
ister is important for accurate individual data on cervical cancers.
• The effect of analytical screening failures on cancer incidence is fairly 
small and cannot easily be further decreased without reduction in the 
high overall specificity of screening.
• Considerable variations exist in the balance between the sensitivity and 
specificity of screening laboratories, but these variations are not reflected 
in screening effectiveness. Regular feedback is needed, to improve the 
reproducibility of the cytodiagnosis in the long term and harmonise the 
screening service with respect to cost and the physical and psychological 
burdens caused by the management of abnormal screening tests.
• The effectiveness of organised screening is strongly age-dependent such 
that programme participation at the age of 25 is not associated with a 
reduced risk of cervical cancer in the following screening interval. Ef-
fectiveness seems to persist until the age of 65.
• A large proportion of cervical cancer incidence and most of the mortality 
are due to cancers diagnosed more than five years after the last screening 
invitation, the next largest group consists of non-attenders, and a smaller 
proportion of cancers are diagnosed among women who have attended 
invitational screening.
Even though there are sensitivity issues in cytology, they are alleviated by the com-
bination of regularly repeated tests and the long screen-detectable phase in the 
development of cervical cancer. Our study has shown within the Finnish programme 
setting that most women who develop cervical cancer do so because of lack of screen-
ing rather than on account of errors in the cytodiagnosis. This observation should 
direct further efforts to improvement in the quality assurance and effectiveness of 
cervical cancer screening programmes.
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